| (51) International Patent Classification 6 :

 A01K 67/00, A61K 38/09, C12N 15/00, 15/16, C07H 21/04, C07K 7/06, 14/575, 16/18, 16/26, C12P 21/06, 21/08, G01N 33/53 | **A1** | (11) International Publication Number: **WO 95/12309**

 (43) International Publication Date: 11 May 1995 (11.05.95) |

(21) International Application Number: PCT/US94/12763

(22) International Filing Date: 4 November 1994 (04.11.94)

(30) Priority Data:
08/147,771   5 November 1993 (05.11.93)   US

(71) Applicants (for all designated States except US): THE BOARD OF TRUSTEES OF LELAND STANFORD, JR. UNIV [US/US]; ERSITY:, Suite 350, 900 Welch Road, Palo Alto, CA 94304-1858 (US). STATE OF OREGON, acting by and through THE OREGON STATES BOARD OF HIGHER EDUCATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): FERNALD, Russell, D. [US/US]; 718 Alvarado Row, Stanford, CA 97305 (US). ADELMAN, John, P. [US/US]; 2433 S.W. Mitchell Street, Portland, OR 97201 (US).

(74) Agents: KRUSE, Norman, J. et al.; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th floor, One Market Plaza, San Francisco, CA 94105-1492 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).

Published
With international search report.

(54) Title: NUCLEIC ACIDS ENCODING [His5, Trp7, Tyr8]-GnRH PREPROHORMONE AND [Ser8]-GnRH PREPROHORMONE AND THEIR USES

(57) Abstract

This invention relates to DNA and protein compositions useful, for instance, in the regulation of reproductive function, and which are also useful in the development of transgenic animals with desirable reproductive characteristics. Specifically, this invention relates to DNA and protein compositions for the precursor protein for the chicken II form of gonadotropin-releasing hormone and to the [Ser8]-GnRH preprohormone.

Nucleic Acids Encoding [His^5,Trp^7,Tyr^8]-GnRH Preprohormone and [Ser^8]-GnRH Preprohormone and Their Uses

BACKGROUND OF THE INVENTION

This invention relates to DNA and protein compositions useful, for instance, in the regulation of reproductive function, and which are also useful in the development of transgenic animals with desirable reproductive characteristics. Specifically, this invention relates to DNA and protein compositions for the precursor protein for the chicken II form of gonadotropin-releasing hormone and to the [Ser^8]-GnRH preprohormone.

Gonadotropin-releasing hormone(GnRH) is an important reproductive hormone in vertebrates. GnRH is a neuropeptide which regulates the production of follicle stimulating hormone (FSH) and luteinizing hormone (LH). In mammals, GnRH is produced by the hypothalamus and regulates the release of FSH and LH, which in turn regulate the development and function of the reproductive organs.

There are eight different forms of GnRH that have been identified in different vertebrate species (see figure 1.) For a review of the species distribution and properties of the different forms of GnRH, *See* Sherwood, N.M., *et al.* (1993) *Endocrine Rev.* 14:241-254. For instance, the more recently evolved mammals have a form of GnRH designated mammalian GnRH. A number of primitive placental mammals, nonplacental mammals and other vertebrates have more than one form of GnRH. One form of GnRH that is particularly widespread in this latter group of animals and has been named chicken II GnRH, since it was the second form of GnRH that was discovered in the chicken. This form of GnRH is also known as [His^5,Trp^7,Tyr^8]-GnRH since it has amino acid substitutions in the 5, 7 and 8 positions as compared to mammalian GnRH (see figure 1).

[His^5,Trp^7,Tyr^8]-GnRH is a potent stimulator of reproductive function in a wide variety of species. It is particularly active in fish. [His^5,Trp^7,Tyr^8]-GnRH is the most potent form of GnRH in fish. (See Sherwood, N.M., et al.,

5   supra and Ngamvongchon, S., et al. (1992) Regulatory Peptides 42:63-73.) [His^5,Trp^7,Tyr^8]-GnRH also apparently has significant biological activity in more recently evolved mammals.

One of the problems in fish aquaculture is control

10   of fish reproduction. For some species of fish, it is difficult to induce the fish to reproduce in captivity. Alternatively, it may be difficult to induce fish in captivity to reproduce at the time of year that is normal to the species. One approach to the control of reproduction in fish

15   for aquaculture is the development of transgenic fish by introduction of DNA encoding the [His^5,Trp^7,Tyr^8]-GnRH preprohormone and the [Ser^8]-GnRH preprohormone.

Many of the potential uses of GnRH, for example fish aquaculture, require identification and isolation of the gene

20   encoding the precursor protein from which the peptide is produced. The sequence of the [His^5,Trp^7,Tyr^8]-GnRH and the [Ser^8]-GnRH preprohormones and the sequence of the genes which encode these proteins have not been described in the prior art. Identification of the genes encoding these sequences

25   will facilitate production and use of the decapeptide hormones and other biologically active fragments in a variety of applications. These and other needs are addressed by the present invention.

30   SUMMARY OF THE INVENTION

The present invention provides compositions for isolated nucleic acids encoding vertebrate [His^5,Trp^7,Tyr^8]-GnRH preprohormones and [His^5,Trp^7,Tyr^8]-GnRH preprohormone GAP peptides. The invention also provides for isolated

35   nucleic acids encoding vertebrate [Ser^8]-GnRH preprohormones and [Ser^8]-GnRH preprohormone GAP peptides. In addition, the invention also provides for compositions comprising the above

preprohormone polypeptides. The preprohormone polypeptides
may be, for example, recombinantly produced.

Nucleic acid probes that selectively hybridize to
nucleic acids encoding the above preprohormone polypeptides
5   are also provided. The invention provides methods of
detecting nucleic acids encoding the preprohormone
polypeptides by nucleic hybridization assays utilizing these
probes. Antibodies that are reactive with the preprohormone
polypeptides are provided, along with immunoassay methods
10   based on these antibodies and which detect the preprohormone
polypeptides. These nucleic acid hybridization assays and
immunoassays are useful as measurements of reproductive
function in a variety of different situations.

The invention further provides for transgenic
15   animals created by the introduction of a DNA construct
encoding a vertebrate [His^5,Trp^7,Tyr^8]-GnRH preprohormone or a
[Ser^8]-GnRH preprohormone. These transgenic animals include
fish species useful in aquaculture and farm animal species,
such as chickens and other animals.

20

DEFINITIONS

Abbreviations for the twenty naturally occurring
amino acids follow conventional usage. In the polypeptide
notation used herein, the left-hand direction is the amino
25   terminal direction and the right-hand direction is the
carboxy-terminal direction, in accordance with standard usage
and convention. Similarly, unless specified otherwise, the
left hand end of single-stranded polynucleotide sequences is
the 5' end; the left hand direction of double-stranded
30   polynucleotide sequences is referred to as the 5' direction.
The direction of 5' to 3' addition of nascent RNA transcripts
is referred to as the transcription direction; sequence
regions on the DNA strand having the same sequence as the RNA
and which are 5' to the 5' end of the RNA transcript are
35   referred to as "upstream sequences"; sequence regions on the
DNA strand having the same sequence as the RNA and which are
3' to the 3' end of the RNA transcript are referred to as
"downstream sequences".

The nucleotide codes shown below are used in the nucleic acid sequences of the invention. This code has been adopted by the IUPAC-IUB Biochemical Nomenclature Commission.

Code	Group	Nucleotide(s)
A	A	adenine
C	C	cytosine
G	G	guanine
T	T	thymine
U	U	uracil
Y	C or T(U)	pyrimidine
R	A or G	purine
M	A or C	amino
K	G or T(U)	keto
S	G or C	3 hydrogen bonds
W	A or T(U)	2 hydrogen bonds
H	A or C or T(U)	not-G
B	G or T(U) or C	not-A
V	G or C or A	not-T(U)
D	G or A or T(U)	not-C
N	G,A,C or T(U)	any

The term "nucleic acids", as used herein, refers to either DNA or RNA. "Nucleic acid sequence" or "polynucleotide sequence" refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes both self-replicating plasmids, infectious polymers of DNA or RNA and nonfunctional DNA or RNA.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined

5

sequence used as a basis for a sequence comparison; a
reference sequence may be a subset of a larger sequence, for
example, as a segment of a full-length cDNA or gene sequence
given in a sequence listing, such as the nucleic acid sequence
5   of figure 2, or may comprise a complete cDNA or gene
sequence. Generally, a reference sequence is at least 20
nucleotides in length, frequently at least 25 nucleotides in
length, and often at least 50 nucleotides in length. Since
two polynucleotides may each (1) comprise a sequence (i.e., a
10   portion of the complete polynucleotide sequence) that is
similar between the two polynucleotides, and (2) may further
comprise a sequence that is divergent between the two
polynucleotides, sequence comparisons between two (or more)
polynucleotides are typically performed by comparing sequences
15   of the two polynucleotides over a "comparison window" to
identify and compare local regions of sequence similarity.

A "comparison window", as used herein, refers to a
conceptual segment of at least 20 contiguous nucleotide
positions wherein a polynucleotide sequence may be compared to
20   a reference sequence of at least 20 contiguous nucleotides and
wherein the portion of the polynucleotide sequence in the
comparison window may comprise additions or deletions (i.e.,
gaps) of 20 percent or less as compared to the reference
sequence (which does not comprise additions or deletions) for
25   optimal alignment of the two sequences.

Optimal alignment of sequences for aligning a
comparison window may be conducted by the local homology
algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482,
by the homology alignment algorithm of Needleman and Wunsch
30   (1970) J. Mol. Biol. 48:443, by the search for similarity
method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci.
(USA) 85:2444, by computerized implementations of these
algorithms GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin
Genetics Software Package Release 7.0, Genetics Computer
35   Group, 575 Science Dr., Madison, WI), or by inspection, and
the best alignment (i.e., resulting in the highest percentage
of sequence similarity over the comparison window) generated
by the various methods is selected. Preferred programs for

6

this use include GAP, BESTFIT AND FASTA, with standard
parameters.

The term "sequence identity" means that two
polynucleotide sequences are identical (i.e., on a nucleotide-
by-nucleotide basis) over the window of comparison. The term
"percentage of sequence identity" is calculated by comparing
two optimally aligned sequences over the window of comparison,
determining the number of positions at which the identical
nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both
sequences to yield the number of matched positions, dividing
the number of matched positions by the total number of
positions in the window of comparison (i.e., the window size),
and multiplying the result by 100 to yield the percentage of
sequence identity.

The terms "substantial identity" or "substantial
sequence identity" as applied to nucleic acid sequences and as
used herein and denote a characteristic of a polynucleotide
sequence, wherein the polynucleotide comprises a sequence that
has at least 85 percent sequence identity, preferably at least
90 to 95 percent sequence identity, more usually at least 99
percent sequence identity as compared to a reference sequence
over a comparison window of at least 20 nucleotide positions,
frequently over a window of at least 25-50 nucleotides,
wherein the percentage of sequence identity is calculated by
comparing the reference sequence to the polynucleotide
sequence which may include deletions or additions which total
20 percent or less of the reference sequence over the window
of comparison. The reference sequence may be a subset of a
larger sequence, for example, as a segment of the full-length
[His[5],Trp[7],Tyr[8]]-GnRH and [Ser[8]]-GnRH sequences disclosed
herein.

As applied to polypeptides, the terms "substantial
identity" or "substantial sequence identity" mean that two
peptide sequences, when optimally aligned, such as by the
programs GAP or BESTFIT using default gap weights, share at
least 80 percent sequence identity, preferably at least 90
percent sequence identity, more preferably at least 95 percent
sequence identity or more (e.g., 99 percent sequence

identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.

5   For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of

10   amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids

15   substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

The term "isolated" or "substantially pure" means a compound is the predominant species present (*i.e.*, on a molar

20   basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially

25   pure composition will comprise more than about 80 to 90 percent of all macromolecular species present in the composition. Most preferably, the species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein

30   the composition consists essentially of a single macromolecular species. For example, "isolated" or "substantially pure", when referring to nucleic acids, refers to those that have been purified away from other chromosomal or extrachromosomal DNA or RNA by standard techniques,

35   including alkaline/SDS treatment, CsCl banding, column chromatography, and other techniques well known in the art. *See*, F. Ausubel, *et al.*, ed. *Current Protocols in Molecular*

8

Biology, Greene Publishing and Wiley-Interscience, New York
(1987), incorporated herein by reference.

"Nucleic acid probes" may be DNA or RNA fragments.
DNA fragments prepared, for example, by digesting plasmid DNA,
5   or by use of PCR, or synthesized by either the phosphoramidite
method described by Beaucage and Carruthers, *Tetrahedron Lett.*
22:1859-1862 (1981), or by the triester method according to
Matteucci, *et al., J. Am. Chem. Soc.,* 103:3185 (1981), both
incorporated herein by reference. A double stranded fragment
10   may then be obtained, if desired, by annealing the chemically
synthesized single strands together under appropriate
conditions or by synthesizing the complementary strand using
DNA polymerase with an appropriate primer sequence. Where a
specific sequence for a nucleic acid probe is given, it is
15   understood that the complementary strand is also identified
and included. The complementary strand will work equally well
in situations where the target is a double-stranded nucleic
acid.

The phrase "selectively hybridizing to" refers to a
20   nucleic acid probe that hybridizes, duplexes or binds only to
a particular target DNA or RNA sequence when the target
sequences are present in a preparation of total cellular DNA
or RNA. "Complementary" or "target" nucleic acid sequences
refer to those nucleic acid sequences which selectively
25   hybridize to a nucleic acid probe. Proper annealing
conditions depend, for example, upon a probe's length, base
composition, and the number of mismatches and their position
on the probe, and must often be determined empirically. For
discussions of nucleic acid probe design and annealing
30   conditions, see, for example, Sambrook *et al., Molecular
Cloning: A Laboratory Manual* (2nd ed.), Vols. 1-3, Cold Spring
Harbor Laboratory, (1989) or *Current Protocols in Molecular
Biology*, F. Ausubel *et al.,* ed. Greene Publishing and Wiley-
Interscience, New York (1987).

35   The phrase "nucleic acid sequence encoding" refers
to a nucleic acid which directs the expression of a specific
protein or peptide. The nucleic acid sequences include both
the DNA strand sequence that is transcribed into RNA and the

RNA sequence that is translated into protein. The nucleic
acid sequences include both the full length nucleic acid
sequences as well as non-full length sequences derived from
the full length protein. It being further understood that the
5   sequence includes the degenerate codons of the native sequence
or sequences which may be introduced to provide codon
preference in a specific host cell.

The phrase "expression cassette", refers to
nucleotide sequences which are capable of affecting expression
10 of a structural gene in hosts compatible with such sequences.
Such cassettes include at least promoters and optionally,
transcription termination signals. Additional factors
necessary or helpful in effecting expression may also be used
as described herein.

15   The term "operably linked" as used herein refers to
linkage of a promoter upstream from a DNA sequence such that
the promoter mediates transcription of the DNA sequence.

The term "vector", refers to viral expression
systems, autonomous self-replicating circular DNA (plasmids),
20 and includes both expression and nonexpression plasmids.
Where a recombinant microorganism or cell culture is described
as hosting an "expression vector," this includes both
extrachromosomal circular DNA and DNA that has been
incorporated into the host chromosome(s). Where a vector is
25 being maintained by a host cell, the vector may either be
stably replicated by the cells during mitosis as an autonomous
structure, or is incorporated within the host's genome.

The term "plasmid" refers to an autonomous circular
DNA molecule capable of replication in a cell, and includes
30 both the expression and nonexpression types. Where a
recombinant microorganism or cell culture is described as
hosting an "expression plasmid", this includes both
extrachromosomal circular DNA molecules and DNA that has been
incorporated into the host chromosome(s). Where a plasmid is
35 being maintained by a host cell, the plasmid is either being
stably replicated by the cells during mitosis as an autonomous
structure or is incorporated within the host's genome.

The phrase "recombinant protein" or "recombinantly produced protein" refers to a peptide or protein produced using non-native cells that do not have an endogenous copy of DNA able to express the protein. The cells produce the

5   protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence. The recombinant protein will not be found in association with proteins and other subcellular components normally associated with the cells producing the protein.

10   "Specifically immunoreactive" refers to a binding reaction between an antibody and antigen which is determinative of the presence of the antigen in the presence of a heterogeneous population of proteins and other biological macromolecules or in a biological sample. Thus, under

15   designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular

20   protein. For example, antibodies raised to the *H. burtoni* [His^5,Trp^7,Tyr^8]-GnRH preprohormone with the amino acid sequence depicted in Seq. ID No. 2 or to the treeshrew [His^5,Trp^7,Tyr^8]-GnRH preprohormone sequence depicted in Seq. ID No. 18 can be selected to obtain antibodies specifically

25   immunoreactive with [His^5,Trp^7,Tyr^8]-GnRH preprohormone proteins and not to other proteins. Homologous proteins to the *H. burtoni* [His^5,Trp^7,Tyr^8]-GnRH preprohormone and the treeshrew [His^5,Trp^7,Tyr^8]-GnRH preprohormone encompass [His^5,Trp^7,Tyr^8]-GnRH preprohormone species, but do not

30   include other proteins. Similarly, antibodies raised to the *H. burtoni* [Ser^8]-GnRH preprohormone with the amino acid sequence depicted in Seq. ID No. 20 can be selected to obtain antibodies specifically immunoreactive with [Ser^8]-GnRH preprohormone proteins and not to other proteins. Homologous

35   proteins to the *H. burtoni* [Ser^8]-GnRH preprohormone encompass [Ser^8]-GnRH preprohormone species, but do not include other proteins.

A variety of immunoassay formats may be used to
select antibodies specifically immunoreactive with a
particular protein. For example, solid-phase ELISA
immunoassays are routinely used to select monoclonal
5   antibodies specifically immunoreactive with a protein. See
Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold
Spring Harbor Publications, New York, for a description of
immunoassay formats and conditions that can be used to
determine specific immunoreactivity.

10   "Biological sample" as used herein refers to any
sample obtained from a living organism or from an organism
that has died. Examples of biological samples include body
fluids and tissue specimens.

15   BRIEF DESCRIPTION OF THE DRAWINGS
             Fig. 1A is a comparison of known GnRH amino acid
sequences. The primary structures of the eight known GnRH
forms and of the first nine amino-terminal residues from yeast
α-mating factor are shown.

20   Fig. 1B shows the predicted amino acid sequence of
the preprohormone for *H. burtoni* [Trp^7,Leu^8]-GnRH as compared
with the [His^5,Trp^7,Tyr^8]-GnRH peptide. The two residues at
which these forms differ are indicated in bold print.
Degenerate 5' oligonucleotides used for PCR are shown below.

25   Fig. 2 shows the cDNA and predicted amino acid
sequence of *H. burtoni* prepro[His^5,Trp^7,Tyr^8]-GnRH. The
functional domains of prepro[His^5,Trp^7,Tyr^8]-GnRH are
illustrated and compared to *H. burtoni* prepro[Trp^7,Leu^8]-GnRH.
Amino acids are numbered beginning at the first residue in the
30   GnRH decapeptide. The functional domains of both
preprohormones are illustrated. Hydrophobic signal sequences
(negative numbers) are directly followed by the GnRH
decapeptide region (bold) and residues involved with
posttranslational processing. The GAP peptide sequences
35   follow the decapeptide and posttranslational processing
sequences. A second processing site (underlined) indicates
coding sequences for two novel peptides in the
[His^5,Trp^7,Tyr^8]-GnRH preprohormone.

Fig. 3 shows the results of high stringency Northern blot analysis using total RNA from ventral, dorsal or whole brain, hybridized to ^{32}P-labelled prepro[His^5,Trp^7,Tyr^8]-GnRH riboprobe. Lanes 1, 2, and 3 were loaded with 5, 10 and 20 µg, respectively, of total RNA extracted from a pool of 3 brains. Lanes 4 through 7 contain 10 µg of total RNA each from one half of a single brain. Lanes 4 and 6 contain ventral brain RNA while lanes 5 and 7 contain RNA from the corresponding dorsal halves. One band of approximately 530 bases is seen in lanes containing ventral or total brain RNA. No signal was detected in total RNA extracted from dorsal brain halves, localizing the expression of this transcript exclusively to more ventral brain regions. Methylene blue staining of ribosomal bands confirmed that the equal amounts of total RNA were loaded into lanes 4-7 of the gel.

Fig. 4 shows localization of prepro [His^5,Trp^7,Tyr^8]-GnRH mRNA in *H. burtoni* brain. TOP: schematic view of a mid-sagittal section from *H. burtoni* brain showing the three populations of neurons immunoreactive for GnRH. For simplicity, the clusters are represented within the same plane although the mesencephalic population lies lateral to both the terminal nerve and POA populations. The terminal nerve GnRH population is indicated by is indicated by ▲, the POA population by ★, and the mesencephalic population by ●.

The bottom six panels show the labelling with each of the two GnRH gene probes in the three brain regions with cells known to contain GnRH from immunocytochemistry. LEFT COLUMN: *in situ* hybridization with a prepro [His^5,Trp^7,Tyr^8]-GnRH digoxygenin-UTP riboprobe. Only the mesencephalic population was labeled. Scale bar = 100 µm. RIGHT COLUMN: *in situ* hybridization with a prepro [Trp^7,Leu^8]-GnRH digoxygenin-UTP riboprobe. Only the terminal nerve population was labeled. Scale bar = 100 µm. Note that neither probe labels the POA/hypothalamic group of cells.

Fig. 5 shows localization of prepro [Ser^8]-GnRH mRNA in *H. burtoni* brain. Midsagittal sections are shown in the panels. The top two panels show hybridization with a prepro [Ser^8]-GnRH riboprobe in subordinate and dominant male fish.

The bottom two panels show hybridization of the riboprobe in the terminal nerve area and the mesencephalon regions of the *H. burtoni* brain of dominant males.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

5   This invention provides isolated nucleic acid sequences encoding precursor proteins for the chicken II form of GnRH, which is referred to here as the [His^5,Trp^7,Tyr^8]-GnRH preprohormone, and for the [Ser^8]-GnRH preprohormone.

10   The sequences can be used in a number of applications. For instance, they can be used for the recombinant production of the preprohormone polypeptides. In addition, transgenic animals (*e.g.*, fish and chickens, and non-human mammals) can be generated using the sequences provided here. Diagnostic

15   assays for detecting nucleic acids encoding the [His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-GnRH preprohormone, as well as assays for these preprohormone proteins are also provided. These assays are particularly useful in the diagnosis of reproductive diseases or

20   reproductive capacity in animals. Compositions and methods for using the sequences provided here are described in more detail below.

A) GnRH preprohormone polypeptides

25   As described above, there are eight different forms of GnRH that have been isolated and characterized from vertebrate species (see figure 1). A precursor for an additional form of GnRH, [Ser^8]-GnRH, is also described herein. Figure 1 shows all decapeptide sequences except

30   [Ser^8]-GnRH with reference to the mammalian GnRH sequence. [Ser^8]-GnRH is a newly discovered form of GnRH, so that there are now 9 known forms of GnRH. Residues which differ from those in the mammalian form are identified both by position and residue. Thus, teleost GnRH is referred to as

35   [Trp^7,Leu^8]-GnRH because, in teleosts, the Leu in position 7 is Trp and the Arg in position 8 is Leu when compared with the mammalian GnRH sequence. As can be seen in GnRH, positions 1,

2, 4, 9, and 10 are invariant, and positions 3 and 7 show only conservative changes.

The predicted amino acid sequence for the [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone from the teleost fish, *H.*

5   *burtoni*, is shown in Figure 2 (Seq. ID No. 2). In addition, the predicted amino acid sequence for the treeshrew [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone is shown in Seq ID No. 18. The precursor of a additional form of GnRH, [Ser⁸]-GnRH, is shown in Seq. ID No. 20. The GnRH preprohormones have a

10   characteristic structure consisting of three separate domains. The N-terminal domain consists of a signal peptide region which is a common feature of many secretory proteins. The second domain consists of the [His⁵,Trp⁷,Tyr⁸]-GnRH decapeptide followed immediately by a 3 amino acid amidation

15   and precursor processing site. The third, C-terminal, domain consists of a GnRH associated peptide or GAP peptide. The GAP peptide region of the [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone may generate two peptides because of an additional potential proteolytic processing site in this region of the

20   preprohormone. Thus, a single [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone GAP peptide consisting of the entire sequence of this region of the protein may be produced. Alternatively, there may be two [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone GAP peptides present.

25   The [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone and the [Ser⁸]-GnRH preprohormone represent two members of a family of GnRH preprohormones. Homology between the *H. burtoni* and the treeshrew [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormones and the *H. burtoni* [Ser⁸]-GnRH preprohormone was determined by the FASTA

30   and GAP computer programs (version 7.3 Unix, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA). Using this procedure there is a 59% homology, and a 44% amino acid identity between the amino acid sequences of *H. burtoni* and treeshrew [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormones. Also using

35   this procedure, there is a 55% homology and a 33% identity between the amino acid sequences of the *H. burtoni* [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone and the *H. burtoni* [Ser⁸]-GnRH preprohormone.

The terms "[His^5,Trp^7,Tyr^8]-GnRH preprohormone",
"[His^5,Trp^7,Tyr^8]-GnRH preprohormone polypeptides" or "chicken
II GnRH preprohormone" as used herein refer to all polypeptide
precursor forms of [His^5,Trp^7,Tyr^8]-GnRH, but exclude the
5   mature [His^5,Trp^7,Tyr^8]-GnRH decapeptide. Similarly, the
terms "[Ser^8]-GnRH preprohormone" or "[Ser^8]-GnRH
preprohormone polypeptides" as used herein refer to all
polypeptide precursor forms of [Ser^8]-GnRH, but exclude the
mature [Ser^8]-GnRH decapeptide. These terms also refer to
10   biologically active fragments of the precursor proteins for
[His^5,Trp^7,Tyr^8]-GnRH and [Ser^8]-GnRH respectively.
Significant biological activities include GnRH activity,
latent GnRH activity and immunological activity. Latent GnRH
activity means that the biologically active fragment can be
15   proteolytically processed to yield active GnRH.
        Immunological activity refers to immunoreactivity
with an antibody raised to a full-length [His^5,Trp^7,Tyr^8]-GnRH
or [Ser^8]-GnRH preprohormone or to segments of these
preprohormones. A segment of a [His^5,Trp^7,Tyr^8]-GnRH
20   preprohormone or [Ser^8]-GnRH preprohormone will ordinarily
comprise at least about 5 contiguous amino acids, typically at
least about 7 contiguous amino acids, more typically at least
about 9 contiguous amino acids, usually at least about 11
contiguous amino acids, preferably at least about 13
25   contiguous amino acids, more preferably at least about 16
contiguous amino acids, and most preferably at least about 20
to 30 or more contiguous amino acids from the preprohormone.
Segments of a particular domain will be segments of the
appropriate size within the corresponding domain.
30   Biologically active fragments include the [His^5,Trp^7,Tyr^8]-
GnRH preprohormone and [Ser^8]-GnRH preprohormone GAP peptide
or peptides.
        The terms "GnRH related peptide", "GAP" or "GAP
peptide" refer to the peptide of the C-terminal domain of a
35   GnRH preprohormone, as described above for the
[His^5,Trp^7,Tyr^8]-GnRH preprohormone and the [Ser^8]-GnRH
preprohormone. Previously known GAP peptides are further
described in Sherwood, N.A., et al., supra. The terms

16

"[His^5,Trp^7,Tyr^8]-GnRH preprohormone GAP peptide" or "chicken
II GnRH preprohormone GAP peptide" refer to the GAP peptide or
peptides derived from the [His^5,Trp^7,Tyr^8]-GnRH preprohormone.
The term "[Ser^8]-GnRH preprohormone GAP peptide" refers to the
5   GAP peptide or peptides derived from the [Ser^8]-GnRH
preprohormone. The [His^5,Trp^7,Tyr^8]-GnRH preprohormone and
[Ser^8]-GnRH preprohormone GAP peptides are produced by the
proteolytic processing of [His^5,Trp^7,Tyr^8]-GnRH preprohormone
and [Ser^8]-GnRH preprohormone, respectively. The
10   [His^5,Trp^7,Tyr^8]-GnRH preprohormone GAP peptide is a
biologically active [His^5,Trp^7,Tyr^8]-GnRH preprohormone
fragment, as defined above, and is therefore included in the
definition of [His^5,Trp^7,Tyr^8]-GnRH preprohormone
polypeptides. Similarly, the [Ser^8]-GnRH preprohormone GAP
15   peptide is a biologically active [Ser^8]-GnRH preprohormone
fragment, as defined above, and is therefore included in the
definition of [Ser^8]-GnRH preprohormone polypeptides.
         The above-defined terms refer not only to the
protein having the amino acid sequence disclosed here, but
20   also to other proteins that are allelic, nonallelic or species
variants of the *H. burtoni* and treeshrew [His^5,Trp^7,Tyr^8]-GnRH
preprohormones and the *H. Burtoni* [Ser^8]-GnRH preprohormone,
as well as to natural or induced mutant forms of these
proteins. For example, [His^5,Trp^7,Tyr^8]-GnRH preprohormone
25   polypeptides generally show substantial sequence identity
(determined as described above) to the amino acid sequence of
the *H. burtoni* [His^5,Trp^7,Tyr^8]-GnRH preprohormone shown in
figure 2 or to the amino acid sequence of the treeshrew
[His^5,Trp^7,Tyr^8]-GnRH preprohormone shown in Seq. ID No. 18.
30   For example, fish [His^5,Trp^7,Tyr^8]-GnRH preprohormone
polypeptides generally show substantial sequence identity to
the amino acid sequence of the *H. burtoni* [His^5,Trp^7,Tyr^8]-
GnRH preprohormone shown in figure 2, and mammalian
[His^5,Trp^7,Tyr^8]-GnRH preprohormone polypeptides generally
35   show substantial sequence identity (determined as described
above) to the amino acid sequence of the treeshrew
[His^5,Trp^7,Tyr^8]-GnRH preprohormone shown in Seq. ID No. 18.
Similarly, [Ser^8]-GnRH preprohormone polypeptides generally

show substantial sequence identity to the amino acid sequence of the *H. burtoni* [Ser^8]-GnRH preprohormone shown in Seq ID No. 20.

[His^5,Trp^7,Tyr^8]-GnRH preprohormone polypeptides
5   will also typically be specifically im noreactive with antibodies raised against the *H. burtc.* [His^5,Trp^7,Tyr^8]-GnRH preprohormone of figure 2 or against the treeshrew [His^5,Trp^7,Tyr^8]-GnRH preprohormone shown in Seq. ID No. [???]. In particular, fish [His^5,Trp^7,Tyr^8]-GnRH
10   preprohormone polypeptides will typically be specifically immunoreactive with antibodies raised against the *H. burtoni* [His^5,Trp^7,Tyr^8]-GnRH preprohormone of figure 2, and mammalian [His^5,Trp^7,Tyr^8]-GnRH preprohormone polypeptides will typically be specifically immunoreactive with antibodies
15   raised against the treeshrew [His^5,Trp^7,Tyr^8]-GnRH preprohormone shown in Seq. ID No. 18. Similarly, [Ser^8]-GnRH preprohormone polypeptides will generally be specifically immunoreactive with antibodies raised against the *H. burtoni* [Ser^8]-GnRH preprohormone shown in Seq. ID No. 20.
20   A [His^5,Trp^7,Tyr^8]-GnRH preprohormone that specifically binds to or that is specifically immunoreactive to an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of Seq. ID No. 2 or Seq. ID No. 18 is determined in an immunoassay. The
25   immunoassay uses a polyclonal antiserum which was raised to the protein of Seq. ID No. 2 or Seq. ID No. 18. This antiserum is selected to have low crossreactivity against GnRH preprohormones other than [His^5,Trp^7,Tyr^8]-GnRH preprohormones. Crossreactivity to these other forms of GnRH
30   preprohormone is removed by immunoabsorption prior to use in the immunoassay.

In order to produce antisera to [His^5,Trp^7,Tyr^8]-GnRH precursor for use in an immunoassay, the proteins of Seq ID No. 2 and Seq. ID No. 18 are isolated as describ d herein.
35   For example, recombinant protein is produced in a mammaliar cell line. An inbred strain of mice such as balb/c or rab are immunized with the protein of Seq. ID No. 2 or Seq. I: No. 18 using a standard adjuvant, such as Freund's adjuvant,

and a standard mouse immunization protocol (see Harlow and
Lane, *supra*). Polyclonal sera are collected and titered
against the immunogen protein in an immunoassay, for example,
a solid phase immunoassay with the immunogen immobilized on a
solid support. Polyclonal antisera with a titer of 10^4 or
greater are selected and tested for their cross reactivity
against GnRH preprohormones other than [His^5,Trp^7,Tyr^8]-GnRH
preprohormone, using a competitive binding immunoassay such as
the one described in Harlow and Lane, *supra*, at pages 570-573.
Three non-[His^5,Trp^7,Tyr^8]-GnRH preprohormones are used in
this determination: the mammalian GnRH preprohormone obtained
from human, rat, and mouse (see Sherwood, *et al.* (1993),
supra); the [Trp^7,Leu^8]-GnRH preprohormone obtained from
Salmon and *H. burtoni*, and the [Ser^8]-GnRH preprohormone
obtained from *H. burtoni*. These non-[His^5,Trp^7,Tyr^8]-GnRH
preprohormones can be produced as recombinant proteins and
isolated using standard molecular biology and protein
chemistry techniques as described herein.

Immunoassays in the competitive binding format can
be used for the crossreactivity determinations. For example,
the protein of Seq. ID No. 2 or Seq. ID No. 18 can be
immobilized to a solid support. Proteins added to the assay
compete with the binding of the antisera to the immobilized
antigen. The ability of the above proteins to compete with
the binding of the antisera to the immobilized protein is
compared to the protein of Seq. ID No. 2 or Seq. ID No. 18.
The percent crossreactivity for the above proteins is
calculated, using standard calculations. Those antisera with
less than 10% crossreactivity with each of the proteins listed
above are selected and pooled. Antisera raised against the
protein of Seq ID No. 2 and the protein of Seq. ID No. 18 are
pooled separately. The cross-reacting antibodies are then
removed from the pooled antisera by immunoabsorption with the
above-listed proteins.

The immunoabsorbed and pooled antisera are then used
in a competitive binding immunoassay as described above to
compare a second protein to the immunogen protein. In order
to make this comparison, the two proteins are each assayed at

a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. For example, if the amount of the second protein required is less than 10 times the

5 amount of the protein of Seq. ID No. 2 required, then the second protein is said to specifically bind to an antibody generated to an immunogen consisting of the protein of Seq. ID No. 2.

A [Ser[8]]-GnRH preprohormone that specifically binds

10 to or that is specifically immunoreactive to an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of Seq. ID No. 20 can also determined in an immunoassay, by using a procedure similar to that described above for [His[5],Trp[7],Tyr[8]]-GnRH

15 preprohormones. In this case, however, polyclonal antisera are selected and tested for their cross reactivity against GnRH preprohormones other than [Ser[8]]-GnRH preprohormone. The non-[Ser[8]]-GnRH preprohormones used in this determination are: the mammalian GnRH preprohormone obtained from human, rat, and

20 mouse (see Sherwood, et al. (1993), supra); the [Trp[7],Leu[8]]-GnRH preprohormone obtained from Salmon and H. burtoni, and the [His[5],Trp[7],Tyr[8]]-GnRH preprohormone obtained from H. burtoni and the treeshrew.

25 B. Nucleic acid compositions for [His[5],Trp[7],Tyr[8]]-GnRH and [Ser[8]]-GnRH preprohormone polypeptides

This invention relates to isolated nucleic acid sequences encoding [His[5],Trp[7],Tyr[8]]-GnRH preprohormone and [Ser[8]]-GnRH preprohormone polypeptides. The nucleic acid

30 compositions of this invention, whether RNA, cDNA, genomic DNA, or a hybrid of the various combinations, may be isolated from natural sources or may be synthesized in vitro. The nucleic acids claimed may be present in transformed or transfected whole cells, in a transformed or transfected cell

35 lysate, or in a partially purified or substantially pure form.

The nucleic acid sequences of the invention are typically identical to or show substantial sequence identity (determined as described above) to the nucleic acid sequence

of SEQ ID. No. 1, Seq. ID No. 17, or Seq. ID No. 19. For
example, nucleic acids encoding [His^5,Trp^7,Tyr^8]-GnRH
preprohormone polypeptides and which show substantial sequence
identity to Seq. ID No. 1 will typically hybridize to the
5   nucleic acid sequence of Seq. ID No. 1 under stringent
conditions. Similarly, nucleic acids encoding
[His^5,Trp^7,Tyr^8]-GnRH preprohormone polypeptides and which
show substantial sequence identity to Seq. ID No. 17 will
typically hybridize to the nucleic acid sequence of Seq. ID
10   No. 17 under stringent conditions. With regard to [Ser^8]-GnRH
preprohormones, nucleic acids encoding [Ser^8]-GnRH
preprohormone polypeptides and which show substantial sequence
identity to Seq. ID No. 19 will typically hybridize to the
nucleic acid sequence of Seq. ID No. 19 under stringent
15   conditions. Stringent conditions are sequence dependent and
will be different in different circumstances. Generally,
stringent conditions are selected to be about 5° C lower than
the thermal melting point (Tm) for the specific sequence at a
defined ionic strength and pH. The Tm is the temperature
20   (under defined ionic strength and pH) at which 50% of the
target sequence hybridizes to a perfectly matched probe.
Typically, stringent conditions will be those in which the
salt concentration is at least about 0.02 molar at pH 7 and
the temperature is at least about 60°C. As other factors may
25   significantly affect the stringency of hybridization,
including, among others, base composition and size of the
complementary strands, the presence of organic solvents and
the extent of base mismatching, the combination of parameters
is more important than the absolute measure of any one.
30   Techniques for nucleic acid manipulation of genes
encoding these polypeptides such as subcloning nucleic acid
sequences encoding polypeptides into expression vectors,
labelling probes, DNA hybridization, and the like are
described generally in Sambrook, *et al.*, *Molecular Cloning - A*
35   *Laboratory Manual* (2nd Ed.), Vol. 1-3, Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York, 1989, which is
incorporated herein by reference. This manual is hereinafter
referred to as "Sambrook, *et al.*"

There are various methods of isolating the DNA
sequences encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone and
[Ser^8]-GnRH preprohormone polypeptides. For example, the DNA
is isolated from a genomic or cDNA library using labelled
5   oligonucleotide probes having sequences complementary to the
sequences disclosed here. Restriction endonuclease digestion
of genomic DNA or cDNA containing the [His^5,Trp^7,Tyr^8]-GnRH
preprohormone gene or the [Ser^8]-GnRH preprohormone gene can
be used to isolate nucleic acids encoding these proteins.
10   Since the DNA sequences encoding [His^5,Trp^7,Tyr^8]-GnRH and
[Ser^8]-GnRH preprohormones are provided here, a panel of
restriction endonucleases can be constructed to give cleavage
of the DNA in the desired regions. After restriction
endonuclease digestion, DNA encoding [His^5,Trp^7,Tyr^8]-GnRH and
15   [Ser^8]-GnRH preprohormones is identified by its ability to
hybridize with nucleic acid probes, for example on Southern
blots, and these DNA regions are isolated by standard methods
familiar to those of skill in the art. See Sambrook, et al.
Various methods of amplifying target sequences, such
20   as the polymerase chain reaction can also be used to prepare
[His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH preprohormone DNA.
Polymerase chain reaction technology (PCR) is used to amplify
nucleic acid sequences of the [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-
GnRH preprohormone polypeptides directly from mRNA, from cDNA,
25   and from genomic libraries or cDNA libraries. The isolated
sequences encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone or
[Ser^8]-GnRH preprohormone may also be used as templates for
PCR amplification.
Appropriate primers and probes for amplifying
30   nucleic acids encoding nucleic acids encoding the
[His^5,Trp^7,Tyr^8]-GnRH or the [Ser^8]-GnRH preprohormone
polypeptides can be generated from analysis of the DNA
sequences. In brief, oligonucleotide primers complementary to
the two 3' borders of the DNA region to be amplified are
35   synthesized. The polymerase chain reaction is then carried
out using the two primers. See PCR Protocols: A Guide to
Methods and Applications. (Innis, M, Gelfand, D., Sninsky, J.
and White, T., eds.), Academic Press, San Diego (1990).

Primers can be selected to amplify the entire regions encoding
the full-length [His[5],Trp[7],Tyr[8]]-GnRH or [Ser[8]]-GnRH
preprohormones or to amplify smaller DNA segments of these
preprohormones as desired.

5   Oligonucleotides for use as probes are chemically
synthesized according to the solid phase phosphoramidite
triester method first described by Beaucage, S.L. and
Carruthers, M.H., 1981, *Tetrahedron Letts.*, 22(20):1859-1862
using an automated synthesizer, as described in

10   Needham-VanDevanter, D.R., *et al.*, 1984, *Nucleic Acids Res.*,
12:6159-6168. Purification of oligonucleotide is by either
native acrylamide gel electrophoresis or by anion-exchange
HPLC as described in Pearson, J.D. and Regnier, F.E., 1983, *J.
Chrom.*, 255:137-149.

15   The sequence of the synthetic oligonucleotide can be
verified using the chemical degradation method of Maxam, A.M.
and Gilbert, 1980, in W., Grossman, L. and Moldave, D., eds.
Academic Press, New York, *Methods in Enzymology*, 65:499-560.
           Other methods known to those of skill in the art may

20   also be used to produce and isolate nucleic acids encoding
[His[5],Trp[7],Tyr[8]]-GnRH preprohormone or [Ser[8]]-GnRH
preprohormone. *See* Sambrook, *et al.* for a description of
other techniques for the isolation of DNA encoding specific
protein molecules.

25

C. Expression of [His[5],Trp[7],Tyr[8]]-GnRH preprohormone and
[Ser[8]]-GnRH preprohormone.
           Once the DNA encoding [His[5],Trp[7],Tyr[8]]-GnRH
preprohormone or the [Ser[8]]-GnRH preprohormone is isolated and

30   cloned, one may express these preprohormones in a variety of
recombinantly engineered cells. It is expected that those of
skill in the art are knowledgeable in the numerous expression
systems available for expression of the DNA encoding these
preprohormones. No attempt to describe in detail the various

35   methods known for the expression of proteins in prokaryotes or
eukaryotes is made here.
           In brief summary, the expression of natural or
synthetic nucleic acids encoding [His[5],Trp[7],Tyr[8]]-GnRH or

[Ser^8]-GnRH preprohormone will typically be achieved by
operably linking the DNA or cDNA to a promoter (which is
either constitutive or inducible), followed by incorporation
into an expression vector. The vectors can be suitable for
5   replication and integration in either prokaryotes or
eukaryotes. Typical expression vectors contain transcription
and translation terminators, initiation.sequences, and
promoters useful for regulation of the expression of the
polynucleotide sequence encoding [His^{5}Trp^7,Tyr^8]-GnRH or
10   [Ser^8]-GnRH preprohormone polypeptides. To obtain high level
expression of a cloned gene, such as those polynucleotide
sequences encoding [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH
preprohormone, it is desirable to construct expression
plasmids which contain, at the minimum, a strong promoter to
15   direct transcription, a ribosome binding site for
translational initiation, and a transcription/translation
terminator. The expression vectors may also comprise generic
expression cassettes containing at least one independent
terminator sequence, sequences permitting replication of the
20   plasmid in both eukaryotes and prokaryotes, *i.e.*, shuttle
vectors, and selection markers for both prokaryotic and
eukaryotic systems. *See* Sambrook *et al.* Examples of
expression of [His^5,Trp^7,Tyr^8]-GnRH and [Ser^8]-GnRH
preprohormone polypeptides in both prokaryotic and eukaryotic
25   systems are described below.

1.   <u>Expression in Prokaryotes</u>
        A variety of procaryotic expression systems may be
used to express [His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-
30   GnRH preprohormone polypeptides. Examples include *E. coli*,
Bacillus, *Streptomyces*, and the like. For example,
[His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH
preprohormone polypeptides may be expressed in *E. coli*. As
another example, these preprohormone polypeptides may be
35   expressed in fish cells. Other fish proteins such as rainbow
trout growth hormone have been successfully expressed in *E.
coli* (*See, e.g.,* Agellon *et al.* (1986) *DNA* 5:463-477 and U.S.
Patent No, 4,849,359).

It is essential to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.

5   Examples of regulatory regions suitable for this purpose in *E. coli* are the promoter and operator region of the *E. coli* tryptophan biosynthetic pathway as described by Yanofsky, C., 1984, *J. Bacteriol.*, 158:1018-1024 and the leftward promoter of phage lambda (P_L) as described by Herskowitz, I. and Hagen,

10   D., 1980, *Ann. Rev. Genet.*, 14:399-445. The inclusion of selection markers in DNA vectors transformed in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol. *See* Sambrook *et al.* for details concerning

15   selection markers for use in *E. coli*.

[His[5],Trp[7],Tyr[8]]-GnRH preprohormone and [Ser[8]]-GnRH preprohormone polypeptides produced by prokaryotic cells may not necessarily fold properly. During purification from *E. coli*, the expressed protein may first be denatured and then

20   renatured. This can be accomplished by solubilizing the bacterially produced proteins in a chaotropic agent such as guanidine HCl and reducing all the cysteine residues with a reducing agent such as beta-mercaptoethanol. The protein is then renatured, either by slow dialysis or by gel filtration.

25   *See* U.S. Patent No.4,511,503.

Detection of the expressed antigen is achieved by methods known in the art as radioimmunoassays, or Western blotting techniques or immunoprecipitation. Purification from *E. coli* can be achieved following procedures described in U.S.

30   Patent No. 4,511,503.

2. Expression in Eukaryotes

A variety of eukaryotic expression systems such as yeast, insect cell lines, bird, fish, and mammalian cells, are

35   known to those of skill in the art. As explained briefly below, [His[5],Trp[7],Tyr[8]]-GnRH preprohormone or [Ser[8]]-GnRH preprohormone polypeptides may also be expressed in these eukaryotic systems.

25

Synthesis of heterologous proteins in yeast is well known and described. *Methods in Yeast Genetics*, Sherman, F., *et al.*, Cold Spring Harbor Laboratory, (1982) is a well recognized work describing the various methods available to

5   produce the preprohormone in yeast.

Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

10 For instance, suitable vectors are described in the literature (Botstein, *et al.*, 1979, *Gene*, 8:17-24; Broach, *et al.*, 1979, *Gene*, 8:121-133).

Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts

15 using zymolyase, lyticase or glusulase, followed by addition of DNA and polyethylene glycol (PEG). The PEG-treated protoplasts are then regenerated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by J.D. Beggs, 1978, *Nature* (London), 275:104-109;

20 and Hinnen, A., *et al.*, 1978, *Proc. Natl. Acad. Sci. USA*, 75:1929-1933. The second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium chloride or acetate and PEG and put on selective plates (Ito, H., *et al.*, 1983, *J. Bact.*, 153:163-168).

25 [His[5],Trp[7],Tyr[8]]-GnRH preprohormone or [Ser[8]]-GnRH preprohormone polypeptides, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot

30 techniques or radioimmunoassays of other standard immunoassay techniques.

The sequences encoding the [His[5],Trp[7],Tyr[8]]-GnRH preprohormone or [Ser[8]]-GnRH preprohormone polypeptides can also be ligated to various expression vectors for use in

35 transforming cell cultures of, for instance, mammalian, insect, bird or fish origin. Illustrative of cell cultures useful for the production of the polypeptides are mammalian cells. Mammalian cell systems often will be in the form of

26

monolayers of cells although mammalian cell suspensions may
also be used. A number of suitable host cell lines capable of
secreting intact proteins have been developed in the art, and
include the CHO cell lines, various human cells such as COS

5   cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc.
Expression vectors for these cells can include expression
control sequences, such as an origin of replication, a
promoter (e.g., a HSV tk promoter or pgk (phosphoglycerate
kinase) promoter), an enhancer (Queen et al. (1986) Immunol.

10   Rev. 89:49), and necessary processing information sites, such
as ribosome binding sites, RNA splice sites, polyadenylation
sites (e.g., an SV40 large T Ag poly A addition site), and
transcriptional terminator sequences.

        Other animal cells useful for production of the

15   preprohormone are available, for instance, from the American
Type Culture Collection Catalogue of Cell Lines and Hybridomas
(7th edition, 1992). For example, fish cells that can be used
include cells derived from rainbow trout, salmon, and the
like. Suitable promoters and vectors are described for

20   instance, in Friedenreich et al., (1990) Nuc. Acids Res.
18:3299-3305.

        Appropriate vectors for expressing preprohormone
polypeptides in insect cells are usually derived from the SF9
baculovirus. Suitable insect cell lines include mosquito

25   larvae, silkworm, armyworm, moth and Drosophila cell lines
such as a Schneider cell line (See Schneider J. Embryol. Exp.
Morphol. 27:353-365 (1987).

        As indicated above, the vector, e.g., a plasmid,
which is used to transform the host cell, preferably contains

30   DNA sequences to initiate transcription and sequences to
control the translation of the preprohormone gene sequence.
These sequences are referred to as expression control
sequences.

        As with yeast, when higher animal host cells are

35   employed, polyadenlyation or transcription terminator
sequences from known mammalian genes need to be incorporated
into the vector. An example of a terminator sequence is the
polyadenlyation sequence from the bovine growth hormone gene.

Sequences for accurate splicing of the transcript may also be
included. An example of a splicing sequence is the VP1 intron
from SV40 (Sprague, J. et al., 1983, J. Virol. 45: 773-781).

      Additionally, gene sequences to control replication
5   in the host cell may be incorporated into the vector such as
those found in bovine papilloma virus type-vectors.
Saveria-Campo, M., 1985, "Bovine Papilloma virus DNA a
Eukaryotic Cloning Vector" in DNA Cloning Vol. II a Practical
Approach Ed. D.M. Glover, IRL Press, Arlington, Virginia pp.
10   213-238.

      The host cells are competent or rendered competent
for transformation by various means. There are several
well-known methods of introducing DNA into animal cells.
These include: calcium phosphate precipitation, fusion of the
15   recipient cells with bacterial protoplasts containing the DNA,
treatment of the recipient cells with liposomes containing the
DNA, DEAE dextran, electroporation and micro-injection of the
DNA directly into the cells.

      The transformed cells are cultured by means well
20   known in the art. Biochemical Methods in Cell Culture and
Virology, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc.,
(1977). The expressed preprohormone polypeptides are isolated
from cells grown as suspensions or as monolayers. The latter
are recovered by well known mechanical, chemical or enzymatic
25   means.

D.   Purification of [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone or
      [Ser⁸]-GnRH preprohormone polypeptides

      The polypeptides produced by recombinant DNA
30   technology may be purified by standard techniques well known
to those of skill in the art. Recombinantly produced
preprohormone polypeptides can be directly expressed or
expressed as a fusion protein. The protein is then purified
by a combination of cell lysis (e.g., sonication) and affinity
35   chromatography. For fusion products, subsequent digestion of
the fusion protein with an appropriate proteolytic enzyme
release the desired polypeptide.

28

The polypeptides of this invention may be purified
to substantial purity by standard techniques well known in the
art, including selective precipitation with such substances as
ammonium sulfate, column chromatography, immunopurification
5   methods, and others. *See*, for instance, R. Scopes, *Protein
Purification: Principles and Practice*, Springer-Verlag: New
York (1982), incorporated herein by reference.

E.   Production of [His^5,Trp^7,Tyr^8]-GnRH preprohormone or
10   [Ser^8]-GnRH preprohormone polypeptides by protein
         chemistry techniques

The polypeptides of the invention can be
synthetically prepared in a wide variety of ways. For
instance polypeptides of relatively short size, can be
15   synthesized in solution or on a solid support in accordance
with conventional techniques. Various automatic synthesizers
are commercially available and can be used in accordance with
known protocols. *See*, for example, Stewart and Young, *Solid
Phase Peptide Synthesis*, 2d. ed., Pierce Chemical Co. (1984).
20

F.   Modification of nucleic acid and polypeptide sequences

The nucleotide sequences used to transfect the host
cells used for production of recombinant preprohormone
polypeptides can be modified according to standard techniques
25   to yield preprohormone polypeptides with a variety of desired
properties. The polypeptides of the present invention can be
readily designed and manufactured utilizing various
recombinant DNA techniques well known to those skilled in the
art. For example, the polypeptides can vary from the
30   naturally-occurring sequence at the primary structure level by
amino acid insertions, substitutions, deletions, and the like.
These modifications can be used in a number of combinations to
produce the final modified protein chain.

The amino acid sequence variants can be prepared
35   with various objectives in mind, including facilitating
purification and preparation of the recombinant polypeptides.
The modified polypeptides are also useful in, for example,
modifying plasma half-life, improving therapeutic efficacy,

and lessening the severity or occurrence of side effects
during therapeutic use. The amino acid sequence variants are
usually predetermined variants not found in nature but exhibit
the same immunogenic activity as naturally occurring

5   polypeptides. For instance, polypeptide fragments comprising
only a portion (usually at least about 60-80%, typically 90-
95%) of the primary structure may be produced. In general,
modifications of the sequences encoding the polypeptides may
be readily accomplished by a variety of well-known techniques,

10   such as site-directed mutagenesis (See, Gillman and Smith,
Gene 8:81-97 (1979) and Roberts, S. et al., Nature 328:731-734
(1987)).

G.   Production of Transgenic Non-human Animals

15   The invention also encompasses methods and
polynucleotide constructs which are employed for generating
transgenic non-human animals which express the preprohormone
polypeptides of the invention. The constructs are used to
produce transgenic non-human mammals, birds (e.g., chickens),

20   fish and the like. Incorporation of nucleotide sequences of
the invention allow modification of the reproductive and other
characteristics of the transgenic animals. For example, fish
that do not readily spawn in captivity can be induced to
reproduce.

25   Appropriate constructs and methods for production of
transgenic animals are known. Typically, the coding sequence
of interest is operably linked to expression regulatory
sequences. In such transgenes, the expression regulatory
sequence is at least the minimal sequences required for

30   efficient cell-type specific expression, which generally are
at least a promoter and sequences upstream of the promoter,
which provide for efficient expression in the target cells.
Usually the sequences upstream of the promoter are used
contiguously, although various deletions and rearrangements

35   can be employed. Some desired regulatory elements (e.g.,
enhancers, silencers) may be relatively position-insensitive,
so that the regulatory element will function correctly even if
positioned differently in a transgene than in the

corresponding germline gene. For example, an enhancer may be
located at a different distance from a promoter, in a
different orientation, and/or in a different linear order.
For example, an enhancer that is located 3' to a promoter in
5   germline configuration might be located 5' to the promoter in
a transgene.

Typically, expression regulation sequences are
chosen to produce tissue-specific or cell type-specific
expression of the recombinant DNA. Once a tissue or cell type
10   is chosen for expression, expression regulation sequences are
chosen. Generally, such expression regulation sequences are
derived from genes that are expressed primarily in the tissue
or cell type chosen. Preferably, the genes from which these
expression regulation sequences are obtained are expressed
15   substantially only in the tissue or cell type chosen, although
secondary expression in other tissue and/or cell types is
acceptable if expression of the recombinant DNA in the
transgene in such tissue or cell type is not detrimental to
the transgenic animal.
20   Particularly preferred expression regulation
sequences are those endogenous to the species of animal to be
manipulated. However, expression regulation sequences from
other species such as those from human genes may also be used.
In some instances, the expression regulation sequences and the
25   recombinant DNA sequences (either genomic or cDNA) are from
the same species. Alternatively, the expression regulation
sequences and recombinant DNA sequences (either cDNA or
genomic) are obtained from different species. In such cases,
the expression regulation and recombinant DNA sequence are
30   heterologous to each other.

In certain embodiments, it is desirable to use gene
targeting, mediated by homologous recombination between a
targeting polynucleotide construct and a homologous
chromosomal sequence, to replace an endogenous gene with the
35   gene encoding a mutant of the preprohormone gene. Methods and
materials for preparing such constructs are known by those of
skill in the art and are described in various references.
See, e.g., Thomas et al., Cell 51:503 (1987) and Capecchi,

Science 244:1288 (1989). Homologous targeting constructs have at least one region having a sequence that substantially corresponds to, or is substantially complementary to, a predetermined endogenous target gene sequence (e.g., an exon

5   sequence, an enhancer, a promoter, an intronic sequence, or a flanking sequence of the target gene). Such a homology region serves as a template for homologous pairing and recombination with substantially identical endogenous gene sequence(s). In the targeting of transgenes, such homology regions typically

10 flank the replacement region, which is a region of the targeting transgene that is to undergo replacement with the targeted endogenous gene sequence. Thus, a segment of the targeting transgene flanked by homology regions can replace a segment of the endogenous gene sequence by double crossover

15 homologous recombination.

        The constructs described above are introduced into pluripotent or totipotent cells using standard techniques. Briefly, this technology involves the insertion of the desired transgene construct into an appropriate cell line (*e.g.*,

20 mammalian embryonic stem (ES) cells or fertilized oocytes) that is capable of differentiating into germ cell tissue. Methods of introducing transgenes into embryonal target cells include microinjection of the transgene into the pronuclei of fertilized oocytes or nuclei of ES cells of the non-human

25 animal. Such methods for murine species are well known to those skilled in the art. Alternatively, the transgene may be introduced into an animal by infection of zygotes with a retrovirus containing the transgene (Jaenisch, R. (1976) *Proc. Natl. Acad. Sci. USA* 73:1260-1264).

30   The production of transgenic non-human mammals (*e.g.*, mice, cows, pigs, and the like) are described in International Application No. WO/08216 and Krimpenfort, *et al.*, *Biotechnology* 9:844-847 (1991). Germ l e transgenesis of both chickens and japanese quail has been escribed. For a

35 general description of the production of transgenic birds, *See*, Shuman (1991) *Experientia* 47:897-905.

        In certain preferred embodiments, transgenic fish are generated. A variety of examples of the production of

32

transgenic fish have been reported (*See*, *e.g.*, Guyomard *et al.*
(1989) *Biochimie* 71:857-863 and Rokkones *et al.* (1989) *J.*
Comp. Physiol. B. 158:751-785. Vectors can be constructed
using mammalian promoters, *e.g.*, from the murine

5   metallothionen gene, or viral promoters, *e.g.*, Rous sarcoma
virus and simian virus 40 (*see*, *e.g.*, Stuart *et al.* (1988)
Development 103:403-412 and Yoon *et al.* (1990) *Aquaculture*
85:21-33). Alternatively, vectors comprising entirely piscine
regulatory sequences can be used (Liu *et al.* (1990)

10 *Bio/Technology* 8:1268-1272).

        The appropriate construct comprising an expression
cassette containing the sequences encoding the preprohormone
is introduced by microinjection into recently fertilized eggs
isolated from spawning fish of the appropriate species (*e.g.*,

15 salmon, trout, and the like). The injected embryos are reared
in the appropriate medium and allowed to develop into mature
fish using standard aquacultural techniques.

        Tissue samples from the transgenic animals can be
analyzed using standard techniques for detecting the presence

20 or absence of a target sequence. For instance, Fluorescent In
Situ Hybridization (FISH) can be used to detect the transgene.
Several guides to FISH techniques are available, *e.g.*, Gall *et*
al. Meth. Enzymol., 21:470-480 (1981) and Angerer *et al.* in
Genetic Engineering: Principles and Methods Setlow and

25 Hollaender, Eds. Vol 7, pgs 43-65 (Plenum Press, New York
1985).

        The sequences can also be detected by PCR using
primers and probes specific for the transgene. Standard PCR
methods useful in the present invention are described in *PCR*

30 *Protocols: A Guide to Methods and Applications* (Innis *et al.*,
eds., Academic Press, San Diego).

H.   Pharmaceutical Compositions
        The preprohormone polypeptides (*e.g.*, GAP peptides)

35 of the present invention can also be administered to control
reproductive function. Thus, the polypeptides can be prepared
in pharmaceutical compositions and administered using methods
well known in the art. For instance, the pharmaceutical

compositions can be administered orally with feed for the regulation of reproductive function in farm animals such as chickens. The compositions can also be suitable for parenteral administration. The pharmaceutical compositions

5 can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, and capsules.

Suitable pharmaceutical formulations for use in the

10 present invention are found in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). A variety of pharmaceutical compositions comprising preprohormone polypeptides of the present invention and pharmaceutically effective carriers can be prepared.

15 Pharmaceutical compositions of the invention include nucleic acid sequences encoding the preprohormone inserted into a suitable gene therapy vector. A variety of different gene therapy vectors may be used. Current strategies and vectors for gene therapy are reviewed in Miller A.D, (1992)

20 *Nature*, 357:455-460 and Mulligan, R.C. (1993) *Science* 260:926-932. The gene therapy vector may be delivered to an individual patient, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion). For systemic administration,

25 injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous injection. Suitable formulations for injection are found in *Remington's Pharmaceutical Sciences, supra*. The pharmaceutical compositions are suitable in a variety of drug delivery

30 systems. For a brief review of present methods of drug delivery, *See*, Langer, *Science* 249:1527-1533 (1990) which is incorporated herein by reference.

I. Detection of Nucleic acids encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH preprohormone polypeptides and detection of [His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH preprohormone polypeptides by immunoassays

The present invention provides methods for detecting DNA or RNA encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH preprohormone and for measuring these preprohormones by immunoassay techniques. These methods are useful for two general purposes. First, assays for detection of nucleic acids encoding these preprohormones are important for the isolation these nucleic acids from a variety of species. As described above, it is known that the mature [His^5,Trp^7,Tyr^8]-GnRH hormone is present in a wide range of species (See Sherwood, N.M. et al., supra). Now that the [His^5,Trp^7,Tyr^8]-GnRH preprohormone and [Ser^8]-GnRH cDNA's have been cloned and isolated, nucleic acids encoding these preprohormones may be isolated from a variety of species according to the methods described in section (B) above and by use of the nucleic acid hybridization assays described below. The immunoassays described below may be useful for isolation of nucleic acids encoding the [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH preprohormones by expression cloning methods. See section (B) above and Sambrook, et al.

The assays described below are also useful as in vitro diagnostic assays to determine the reproductive status of farm animals or of fish in aquaculture. For example, testing of fish for [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH preprohormone production at various times may play a role in the regulation of fish reproduction in aquaculture. In addition, the discovery of the [His^5,Trp^7,Tyr^8]-GnRH mature hormone in placental mammals (See Sherwood, N.M., supra) and the demonstration, herein, of the [His^5,Trp^7,Tyr^8]-GnRH preprohormone in the treeshrew suggests that the [His^5,Trp^7,Tyr^8]-GnRH preprohormone may also be produced in humans. Therefore, the assays described below may also be useful in tests for reproductive function in humans.

1. Nucleic Acid Hybridization Assays

A variety of methods for specific DNA and RNA
measurement using nucleic acid hybridization techniques are
known to those of skill in the art. *See* Sambrook, *et al.* For
example, one method for evaluating the presence or absence of
[His^5,Trp^7,Tyr^8]-GnRH preprohormone DNA or [Ser^8]-GnRH
preprohormone DNA in a sample involves a Southern transfer.
Briefly, the digested genomic DNA is run on agarose slab gels
in buffer and transferred to membranes. Hybridization is
carried out using the nucleic acid probes discussed above. As
described above, nucleic acid probes are designed based on the
known nucleic acid sequences encoding the [His^5,Trp^7,Tyr^8]-
GnRH preprohormone or the [Ser^8]-GnRH preprohormone.
Visualization of the hybridized portions allows the
qualitative determination of the presence or absence of DNA
encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-
GnRH preprohormone.

Similarly, a Northern transfer may be used for the
detection of mRNA encoding [His^5,Trp^7,Tyr^8]-GnRH preprohormone
or the [Ser^8]-GnRH preprohormone. In brief, the mRNA is
isolated from a given cell sample using an acid guanidinium-
phenol-chloroform extraction method. The mRNA is then
electrophoresed to separate the mRNA species and the mRNA is
transferred from the gel to a nitrocellulose membrane. As
with the Southern blots, labeled probes are used to identify
the presence or absence of the [His^5,Trp^7,Tyr^8]-GnRH or the
[Ser^8]-GnRH preprohormone transcript.

A variety of nucleic acid hybridization formats are
known to those skilled in the art. For example, common
formats include sandwich assays and competition or
displacement assays. Hybridization techniques are generally
described in "*Nucleic Acid Hybridization, A Practical
Approach,*" Ed. Hames, B.D. and Higgins, S.J., IRL Press, 1985;
Gall and Pardue (1969), *Proc. Natl. Acad. Sci.*, U.S.A.,
63:378-383; and John, Burnsteil and Jones (1969) *Nature*,
223:582-587.

For example, sandwich assays are commercially useful
hybridization assays for detecting or isolating nucleic acid

sequences. Such assays utilize a "capture" nucleic acid covalently immobilized to a solid support and labelled "signal" nucleic acid in solution. The clinical sample will provide the target nucleic acid. The "capture" nucleic acid

5   and "signal" nucleic acid probe hybridize with the target nucleic acid to form a "sandwich" hybridization complex. To be effective, the signal nucleic acid cannot hybridize with the capture nucleic acid.

Typically labelled signal nucleic acids are used to

10   detect hybridization. Complementary nucleic acids or signal nucleic acids may be labelled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with ^3H, ^{125}I, ^{35}S, ^{14}C, or ^{32}P-labelled

15   probes or the like. Other labels include ligands which bind to labelled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labelled ligand.

Detection of a hybridization complex may require the

20   binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal.

25   The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or

30   in some cases, by attachment to a radioactive label. (Tijssen, P., "Practice and Theory of Enzyme Immunoassays," *Laboratory Techniques in Biochemistry and Molecular Biology*, Burdon, R.H., van Knippenberg, P.H., Eds., Elsevier (1985), pp. 9-20.)

35   The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction

(PCR) system and the ligase chain reaction (LCR) system.
Other methods recently described in the art are the nucleic
acid sequence based amplification (NASBA™, Cangene,
Mississauga, Ontario) and Q Beta Replicase systems.

5   An alternative means for determining the level of
expression of the [His^5,Trp^7,Tyr^8]-GnRH preprohormone gene or
the [Ser^8]-GnRH preprohormone is *in situ* hybridization. *In
situ* hybridization assays are well known and are generally
described in Angerer, *et al.*, *Methods Enzymol.*, 152:649-660
10   (1987). In an *in situ* hybridization assay, cells,
preferentially bovine lymphocytes are fixed to a solid
support, typically a glass slide. If DNA is to be probed, the
cells are denatured with heat or alkali. The cells are then
contacted with a hybridization solution at a moderate
15   temperature to permit annealing of labeled probes specific to
[His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-GnRH
preprohormone. The probes are preferably labelled with
radioisotopes or fluorescent reporters.

20   2.   Production of Antibodies and Development of
            Immunoassays

          In addition to detecting expression of the
[His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-GnRH
preprohormone by nucleic acid hybridization, one can also use
25   immunoassays to detect the preprohormones. Immunoassays can
be used to qualitatively or quantitatively analyze for the
preprohormone or to specifically detect the GAP peptide. A
general overview of the applicable technology can be found in
Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring
30   Harbor Pubs., N.Y. (1988), incorporated herein by reference.
            a.   Antibody Production
          A number of immunogens may be used to produce
antibodies specifically reactive with the [His^5,Trp^7,Tyr^8]-
GnRH preprohormone or the [Ser^8]-GnRH preprohormone.
35   Recombinant preprohormone is the preferred immunogen for the
production of monoclonal or polyclonal antibodies. Naturally
occurring preprohormone may also be used either in pure or
impure form. Synthetic peptides made using the

38

[His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-GnRH preprohormone sequences described herein may also used as an immunogen for the production of antibodies to the preprohormone. Preferentially, recombinant [His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH preprohormone or fragments thereof are expressed in bacterial cells as described above, and purified as generally described above. The product is then injected into an animal capable of producing antibodies. Either monoclonal or polyclonal antibodies may be generated, for subsequent use in immunoassays to measure the preprohormone.

Methods of production of polyclonal antibodies are known to those of skill in the art. In brief, an immunogen, preferably a purified protein, is mixed with an adjuvant and animals are immunized. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the [His^5,Trp^7,Tyr^8]-GnRH preprohormone or the [Ser^8]-GnRH preprohormone. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera is prepared. Further fractionation of the antisera to enrich for antibodies reactive to the preprohormone can be done if desired. (*See* Harlow and Lane, *supra*).

Monoclonal antibodies may be obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*See*, Kohler and Milstein, *Eur. J. Immunol.* 6:511-519 (1976), incorporated herein by reference). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.

Methods of production of synthetic peptides are
known to those of skill in the art. Briefly, the predicted
immunogenic regions of .s^5,Trp^7,Tyr^8]-GnRH preprohormone or
[Ser^8]-GnRH preprohormone sequences described herein are

5   identified. For production of antibodies specific to the
[His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH preprohormone GAP
peptides, predicted immunogenic regions of the preprohormone
sequence in the GAP region of the molecule are used (see Seq.
ID No. 2 , Seq ID No. 18 and Seq. ID No 20. Peptides

10   preferably at least 10 amino acids in length are synthesized
corresponding to these regions and the peptides are conjugated
to larger protein molecules for subsequent immunization.
Production of monoclonal or polyclonal antibodies is then
carried out as described above.

15   b.   Immunoassays

Antibodies reactive with a particular protein can be
measured by a variety of immunoassay methods. For a review of
immunological and immunoassay procedures in general, *See Basic
and Clinical Immunology* 7th Edition (D. Stites and A. Terr

20   ed.) 1991. Moreover, the immunoassays of the present
invention can be performed in any of several configurations,
which are reviewed extensively in *Enzyme Immunoassay*, E.T.
Maggio, ed., CRC Press, Boca Raton, Florida (1980); "Practice
and Theory of Enzyme Immunoassays," P. Tijssen, *Laboratory*

25   *Techniques in Biochemistry and Molecular Biology*, Elsevier
Science Publishers B.V. Amsterdam (1985); and, Harlow and
Lane, *Antibodies, A Laboratory Manual*, *supra*, each of which is
incorporated herein by reference.

Immunoassays for measurement of [His^5,Trp^7,Tyr^8]-

30   GnRH preprohormone or [Ser^8]-GnRH preprohormone polypeptides
can be performed by a variety to methods known to those
skilled in the art. In brief, immunoassays to measure the
preprohormones or the GAP peptides can be either competitive
or noncompetitive binding assays. In competitive binding

35   assays, the sample analyte competes with a labeled analyte for
specific binding sites on a capture agent bound to a solid
surface. Preferably the capture agent is an antibody
specifically reactive with the [His^5,Trp^7,Tyr^8]-GnRH

preprohormone or [Ser^8]-GnRH preprohormone produced as
described above. The concentration of labeled analyte bound
to the capture agent is inversely proportional to the amount
of free analyte present in the sample.

5   In a competitive binding immunoassay,
[His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH
preprohormone present in the sample competes with labelled
preprohormone for binding to a specific binding agent, for
example, an antibody specifically reactive with the

10   preprohormone. The binding agent may be bound to a solid
surface to effect separation of bound labelled preprohormone
from the unbound labelled preprohormone. Alternately the
competitive binding assay may be conducted in liquid phase and
any of a variety of techniques known in the art may be used to

15   separate the bound labelled preprohormone from the unbound
labelled preprohormone. Following separation, the amount of
bound labeled preprohormone is determined. The amount of
preprohormone present in the sample is inversely proportional
to the amount of labelled preprohormone binding.

20   Alternatively, a homogenous immunoassay may be
performed in which a separation step is not needed. In these
immunoassays, the label on the preprohormone is altered by the
binding of the preprohormone to its specific binding agent.
This alteration in the labelled protein results in a decrease

25   or increase in the signal emitted by label, so that
measurement of the label at the end of the immunoassay allows
for detection or quantitation of the preprohormone.

[His^5,Trp^7,Tyr^8]-GnRH preprohormone or [Ser^8]-GnRH
preprohormone may also be determined by a variety of

30   noncompetitive immunoassay methods. For example, a two-site,
solid phase sandwich immunoassay is used. In this type of
assay, a binding agent for the preprohormone, for example an
antibody, is attached to a solid phase. A second
preprohormone binding agent, which may also be an antibody,

35   and which binds the preprohormone at a different site, is
labelled. After binding at both sites on the preprohormone
has occurred, the unbound labelled binding agent is removed
and the amount of labelled binding agent bound to the solid

phase is measured. The amount of labelled binding agent bound
is directly proportional to the amount of preprohormone in the
sample.

5   Western blot analysis can also be done to determine
the presence of [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-GnRH
preprohormone in a sample. Electrophoresis is carried out,
for example, on a tissue sample suspected of containing the
preprohormone. Following electrophoresis to separate the
proteins, and transfer of the proteins to a suitable solid
10   support such as a nitrocellulose filter, the solid support is
then incubated with an antibody reactive with the
preprohormone. This antibody may be labeled, or alternatively
may be it may be detected by subsequent incubation with a
second labelled antibody that binds the anti-preprohormone
15   antibody.

The immunoassay formats described above employ
labelled assay components. The label can be in a variety of
forms. The label may be coupled directly or indirectly to the
desired component of the assay according to methods well known
20   in the art. A wide variety of labels may be used. The
component may be labeled by any one of several methods.
Traditionally a radioactive label incorporating ^{3}H, ^{125}I, ^{35}S,
^{14}C, or ^{32}P was used. Non-radioactive labels include ligands
which bind to labelled antibodies, fluorophores,
25   chemiluminescent agents, enzymes, and antibodies which can
serve as specific binding pair members for a labelled ligand.
The choice of label depends on sensitivity required, ease of
conjugation with the compound, stability requirements, and
available instrumentation. For a review of various labelling
30   or signal producing systems which may be used, see U.S. Patent
No. 4,391,904, which is incorporated herein by reference.

This invention also embraces diagnostic kits for
detecting the presence of [His^5, Trp^7,Tyr^8]-GnRH preprohormone
or [Ser^8]-GnRH preprohormone in tissue or blood samples which
35   comprise a container containing antibodies selectively
immunoreactive to the preprohormone and instructional material
for performing the test. This invention further embraces
diagnostic kits for detecting [His^5,Trp^7,Tyr^8]-GnRH or [Ser^8]-

GnRH preprohormone DNA or RNA in tissue or blood samples which
comprise nucleic probes as described herein and instructional
material.

5

EXAMPLES

Example 1: Isolation of a cDNA encoding *H. burtoni*
[His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone

    A)   Development of an oligonucleotide probe specific for
        H. burtoni [His⁵,Trp⁷,Tyr⁸]-GnRH preprohormone cDNA

To obtain nucleotide sequences encoding a
[His⁵,Trp⁷,Tyr⁸]-GnRH-like peptide from *H. burtoni*, we
employed a novel polymerase chain reaction (PCR) strategy
using brain regions known to contain GnRH neuronal populations
(see Fig. 4 for a schematic view of *H. burtoni* brain).
Animals were sacrificed and whole brains removed as described
in White, S.A. & Fernald, R.D. *J. Neurosci.* (1993) 13:434-441.
The dorsal portion of the telencephalon, the optic tectum and
cerebellum from each brain was removed. Total RNA was
isolated from the remaining ventral portions by guanidine
thiocyanate-acid phenol extraction and converted into cDNA
using reverse transcriptase (Superscript, BRL; Gaithesburg,
MD). cDNA synthesis was primed with 0.5 μg of a bipartite
oligonucleotide consisting of a homopolymer of 9 d(T) residues
at the 3' end. The 5' domain comprised a sequence of 14
nucleotides which included a restriction endonuclease
recognition site. The sequence of the oligonucleotide is: 5'
GCAGAAGCTTCAGCT(9) 3' (Seq. ID No. 15).

     The resulting cDNA was used as substrate for nested
PCR. In both rounds of amplification, the downstream primer
was equivalent to the 5' domain of the bipartite
oligonucleotide, described above. In the first PCR reaction,
the upstream primer was a pool of 24 14-mers representing all
possible coding sequences for the first five amino acids of
[His⁵,Trp⁷,Tyr⁸]-GnRH (see figure 1(b)). 12.5 pmol of the
upstream primer was used. After 40 cycles of 94°C/30 s;
55°C/30s; 72°C/15s, 0.05 μl of the product of this reaction
was aliquoted to a second reaction using 12.5 pmol of a new
upstream primer together with the same downstream primer under
the same cycling conditions. The new primer pool of 24 16-
mers consisted of all possible coding combinations for
residues 5-9 of the decapeptide (see figure 1(b)). Reactions

were performed using Taq polymerase (synthesized courtesy of
Dr. R. Moses) on a Perkin-Elmer 9600 thermocycler.
Oligonucleotides were synthesized as needed using an Applied
Biosystems 391 instrument.

5   PCR products were separated using a 1.5% GTG agarose
gel (FMC, Rockville, ME, USA) and products of greater than 300
bases were electrocuted and subcloned into M13 for sequencing
as described in Bond, C.T., Francis, R.C., Fernald, R.D. &
Adelman, J.P. (1991) *J. Mol. Endocrinol.* 5:931-937.

10   Nucleotide sequences were analyzed for the presence of the
second upstream primer (ending in the codon for amino acid 9;
see Fig. 2), followed by a codon for the final conserved amino
acid of the decapeptide, ^{10}Gly, and sequences for the
canonical GnRH amidation and peptide processing site,

15   ^{11}Gly^{12}Lys^{13}Arg. (*See* Douglass, J., Civelli, O. & Herbert, E.
(1984) *Ann. Rev. Biochem.* 53:665-715.)

     A radiolabeled nucleotide probe 29 bases in length
was derived from a putative [His^5,Trp^7,Tyr^8]-GnRH PCR product.
The sequence of this oligonucleotide is

20   GGGAATGCAGCTACCTGAGACCCCAGAGG (Seq. ID No. 16).

     B)   Isolation of a full-length cDNA encoding the *H.*
          burtoni [His^5,Trp^7,Tyr^8]-GnRH preprohormone

          To obtain full-length coding sequences, poly-adenylated

25   RNA was isolated from *H. burtoni* ventral brain regions (see
above) and used to construct a cDNA library in λgt10. 250,000
primary recombinant were screened (Genescreen; NEN-Dupont,
Boston, MA, USA) using the radiolabeled oligonucleotide of Seq
ID No. 16, described above. Positively hybridizing phage were

30   purified by successive rescreens at reduced density. The cDNA
inserts were subcloned into M13 phage and the nucleotide
sequences determined. A cDNA containing the full-length
coding sequence was subcloned into a transcription vector
(Pselect, USB) for generation of sense and antisense

35   riboprobes.

Example 2:   Sequence Analysis of the *H. burtoni* cDNA encoding
the [His[5],Trp[7],Tyr[8]]-GnRH preprohormone

          Six positively hybridizing clones were identified
from the *H. burtoni* ventral brain cDNA library as described
5   above and the nucleotide sequences of the inserts were
determined.   The full-length cDNA sequence is shown in Seq. ID
No. 1, and the predicted amino acid sequence for the *H.*
burtoni chicken II GnRH preprohormone is shown in figure 2
(Seq. ID No. 2).   The longest open reading frame containing
10   the [His[5],Trp[7],Tyr[8]]-GnRH coding sequence begins with a
methionine initiator codon and predicts a 90 amino acid
protein (Fig. 2).   The first 23 residues are largely
hydrophobic and are likely a signal peptide as is found in
many polyprotein neuroendocrine precursors (see Douglass, J.,
15   Civelli, O. & Herbert, E. (1984) *Ann. Rev. Biochem.*
53:665-715.)   The signal sequence is in direct linkage with
[His[5],Trp[7],Tyr[8]]-GnRH, which is followed by Gly[11]Lys[12]Arg[13].
These residues follow the decapeptide sequence in all of the
other cloned GnRH preprohormones and serve as substrates for
20   post-translational processing (*See* Douglass, J., *et al.*,
supra).   The amino acid sequence of the [His[5],Trp[7],Tyr[8]]-GnRH
preprohormone (Seq. ID No. 3) is shown for comparison in
Figure 2.   The remainder of the precursor may code for two
additional peptides also generated by proteolytic processing,
25   neither of which show any homology to sequences in protein
databases.   One peptide, 28 residues in length, is followed by
dibasic residues (arg-arg, see Fig. 2 legend), and the
remaining 19 amino acids could comprise a second processing
product.   There is only about 10% identity between the two *H.*
30   *burtoni* GnRH preprohormones when the GnRH motif is excluded
(see Figure 2).

Example 3: Northern blot analysis of *H. burtoni* brain tissue
for the [His[5],Trp[7],Tyr[8]]-GnRH Precursor

35   Northern blots were prepared as previously described
(see Bond, C.T., Francis, R.C., Fernald, R.D. & Adelman, J.P.
(1991) *J. Mol. Endocrinol.* 5:931-937) and probed with
antisense riboprobes synthesized with SP6 RNA polymerase,

incorporating ^{32}P-labelled UTP to a specific activity of 3 x
10^8 dpm/μg. Hybridizations contained approximately 10^7 dpm
per ml. High stringency conditions were obtained using 50%
formamide at 65°C with washes in 0.1 x SSC at 70°C.

5   Northern blot analysis of total RNA extracted from
dorsal, ventral and whole *H. burtoni* brain revealed a single
transcript of *ca.* 530 bases expressed in ventral and whole
brain but absent from dorsal structures (Fig. 3).
Radiolabelled antisense riboprobes for both the
10   [His^5,Trp^7,Tyr^8]-GnRH and [Trp^7,Leu^8]-GnRH preprohormones were
prepared and used to probe Northern blots of polyA+ RNA
isolated from total brain at both high and low stringencies.
The results (not shown) indicate that the probes for the two
preprohormones do not cross-hybridize at either stringency
15   with the alternative transcript.

Example 4: *In situ hybridization*

          The site of [His^5,Trp^7,Tyr^8]-GnRH mRNA production in
H. burtoni brain was assessed using *in situ* hybridization.
20   Animals were sacrificed, brains removed and tissue fixed as
previously described (*See* White, *et al.*, *J. Neurosci.* (1993)
13:434-44). 40 μm cryostat sections were mounted on poly
L-lysine subbed slides for hybridization to the digoxygenin
UTP (DIG, Boehringer Mannheim) -labeled [His^5,Trp^7,Tyr^8]-GnRH
25   riboprobe. Hybridizations were carried out at high stringency
(55°C in 50% formamide) according to the manufacturer's
instructions with the following modifications: 150 μl of
hybridization solution was applied to slides containing 4 to 5
brain sections. Following hybridization, 3 washes were done
30   in 2 X SSC at 55°C for one hour each, followed by one wash in
1 X SSC for 30 min at room temperature. To prepare the
riboprobe, subcloned prepro[His^5,Trp^7,Tyr^8]-GnRH was
linearized with Eco RI (GIBCO-BRL, Grand Island, New York,
USA), followed by filling in of recessed 3' termini with the
35   Klenow fragment of DNA polymerase I and Proteinase K
treatment. The template DNA was purified using Magic DNA
Clean-Up System (Promega Corporation, Madison, Wisconsin, USA)
and 300 *ng* was used for transcription of a riboprobe with SP6

RNA polymerase (GIBCO-BRL) in the presence of DIG-conjugated
UTP. Final concentrations in a 100μl reaction volume were: 1
X SP6 reaction buffer, 1 X NTP labeling mixture
(Boehringer-Mannheim, Indianapolis, Indiana, USA), 4.0 mM DTT,
5   80 units RNAsin (Promega), 13.2 μg BSA, and 120 units of SP6
polymerase. Solutions for both Northern analysis and *in situ*
hybridizations were prepared using water treated with 0.075%
diethylpyrocarbonate.

         [His^5,Trp^7,Tyr^8]-GnRH mRNA expression, localized
10   using *in situ* hybridization, was found only in a cluster on
neurons found in the mesencephalon (Fig. 4 (TOP)) previously
shown to contain GnRH using immunocytochemistry. Davis, M.R.
& Fernald, R.D., *J. Neurobiol.* (1990) 21:1180-1188.
Interestingly, [His^5,Trp^7,Tyr^8]-GnRH is not expressed in the
15   hypothalamic nucleus (Fig. 4 (LEFT COLUMN)) which projects to
the pituitary and hence probably does not directly influence
gonadotropin activation. The probes for the two species of
GnRH found in *H. burtoni* do not cross-react either when
applied *in situ* (see Fig. 4) or in Northern blots (see above).
20   Thus distinct forms of GnRH encoding genes are expressed in
distinct brain regions.

         In *H. burtoni*, as in other vertebrates, three
neuronal populations have been shown to contain GnRH using
immunocytochemistry: the terminal nerve, the
25   hypothalamic/preoptic area and the mesencephalon. Davis, M.R.
& Fernald, R.D., *J. Neurobiol.* (1990) 21:1180-1188; White,
S.A. & Fernald, R.D., *J. Neurosci.* (1993) 13:434-441; see Fig.
4, TOP). Here we have shown that [His^5,Trp^7,Tyr^8]-GnRH mRNA
is expressed only in the mesencephalic population (Fig. 4,
30   (LEFT COLUMN)). In contrast, [Trp^7,Leu^8]-GnRH mRNA is
localized only in the terminal nerve nucleus of the
telencephalon (Fig. 4 (RIGHT COLUMN)). Furthermore, the lack
of *in situ* hybridization within the GnRH-immunoreactive cells
of the hypothalamic/preoptic area (Fig. 4) reveals that the
35   GnRH-encoding gene expressed there is sufficiently different
to elude detection by either probe. Thus, despite its potent
releasing factor activity (cf. Ngamvongchon, S. Rivier, J.E. &
Sherwood, N.M. (1992), *Regul. Pept.* 42:63-73)),

[His^5,Trp^7,Tyr^8]-GnRH is unlikely to influence pituitary function directly in *H. burtoni*. Moreover, this suggests that yet a third gene encoding for GnRH may be responsible for regulating reproduction directly.

5   The structure of the [His^5,Trp^7,Tyr^8]-GnRH predicts two novel peptides in addition to it, in contrast to the single associated peptide predicted by [Trp^7,Leu^8]-GnRH mRNA (see Figure 2). The lack of homology between the two known GnRH preprohormones in *H. burtoni* suggests that these genes

10   have either evolved independently or diverged from a common ancestor well before the appearance of teleost fish.

          The novel preprohormone structure and extrahypothalamic location of the *H. burtoni* [His^5,Trp^7,Tyr^8]-GnRH precursor may indicate a unique function for this GnRH

15   form and/or its associated peptides. While hypothalamic GnRH clearly functions as a releasing hormone, neuromodulatory and neurotransmitter roles have been postulated for GnRHs in other brain regions (reviewed in Loumaye, E., Thorner, J. & Catt, K.J. (1982) *Science* 218:1323-1325). The localization of the

20   [His^5,Trp^7,Tyr^8]-GnRH mRNA to the mesencephalon supports previous immunological studies in which [His^5,Trp^7,Tyr^8]-GnRH-like peptides were found concentrated in caudal brain areas. Such mesencephalic GnRH-containing neurons may play a role in the central organization of reproductive behavior as suggested

25   for poecilid fish where a similar neuronal population has been described. *See* Miller, K.E. & Kriebel, R.M. (1986) *Gen. Comp. Endocrinol.* 64:396-400. These cells contain GnRH and project to a spinal neurosecretory group which, in turn, has been postulated to play a role in gonadal duct contractility.

30   As noted, only one GnRH peptide (previously called mammalian GnRH), that which regulates the pituitary gonadotropes, has been demonstrated in more recently evolved mammals. This form can be detected in some bony fish, but is absent in *H. burtoni* as well as in reptiles and birds

35   (reviewed in Loumaye, E., Thorner, J. & Catt, K.J. (1982) *Science* 218:1323-1325, *supra*). In contrast, [His^5,Trp^7,Tyr^8]-GnRH has widespread expression among vertebrates with the notable exception of more derived mammals. Since non-

mammalian animals express more than one GnRH peptide, it is possible that many mammals may express more than one form of GnRH, particularly the [Ser^8]-GnRH form.

5   **Example 5: Isolation of a cDNA encoding a treeshrew [His^5,Trp^7,Tyr^8]-GnRH preprohormone**

To isolate the sequence encoding the [His^5,Trp^7,Tyr^8]-GnRH preprohormone isoform in the treeshrew *Tupaia bulangeri*, we used a polymerase chain reaction (PCR)

10   strategy similar to that used in the isolation of this isoform in a teleost fish, *Haplochromis burtoni*, as described Example 1, herein. The amino acid sequence of the [^{5}His,^{7}Trp, ^{8}Try]GnRH decapeptide guided selection of primers for PCR amplification. Treeshrew brain mRNA was primed with a

15   bipartite oligonucleotide for cDNA synthesis. The 3' domain of this oligonucleotide consisted of a homopolymer of d(T)24 residue, while the 5' domain comprised a known sequence of 10 nucleotides which included a restriction endonuclease recognition site. The resulting cDNA was used as substrate

20   for nested PCR. The downstream primer in both rounds of amplification was bipartite. A randomly generated hexamer including all possible combinations of nucleotides at seven positions composed the 3' end and ten known nucleotides, including an Hind III restriction endonuclease recognition

25   site, made up the 5' end. In the first PCR reaction, the upstream primer was a pool of 24 tetradecamers representing all possible coding sequences for the first five amino acids of [His^5,Trp^7,Tyr^8]-GnRH. The sequence of these primers is represented in the following two sequences: GCACGAATTCCA A/G

30   CA T/C TGGTCNCA (Seq. ID No. 21) and GCACGAATTCCA A/G CA T/C TGGAG T/C CA (Seq. ID No. 22). The product of the first PCR reaction served as substrate for nested reactions where the new upstream primer was bipartite. The 5' end of this primer contained a known restriction enzyme recognition sequence

35   while the 3' end comprised a pool of 24 tetradecamers representing all possible coding combinations for residues 5-8 of the decapeptide. These sequence this pool of primers is: GCACGAATTCCA T/C GGNTGGTA T/C CC (Seq. ID No. 23).

PCR products were separated by electrophoresis in a
2.5% GTG agarose gel (FMC) and products > 250 bases
electrocuted and subcloned into M13 phage vector for sequence
analysis (Bond et al., 1991). Nucleotide sequences were

5   analyzed for the presence of the second upstream primer
followed by the codons for the final amino acid of the
decapeptide, Gly, and the next three amino acids Gly, Lys, and
Arg. These residues follow the decapeptide sequence in the
other cloned GnRH preprohormones and serve as substrates for

10   posttranslational processing. One clone contained these
landmarks followed by an open reading frame of 165 (or 219)
nucleotides 55 (or 73) amino acids. The numbers in
parentheses refer to the nucleotide and amino acid length if
the alternate codon using methionine is used as the start

15   codon. To confirm the identity of this clone as the
[His^5,Trp^7,Tyr^8]-GnRH preprohormone, a downstream region of
the clone was chosen from which to generate new primers for 5'
rapid amplification of cDNA ends (RACE). See Frohman et al.
in (1993) Methods in Enzymology Volume 218, Wu, R., editor,

20   Academic Press, Inc., San Diego, California, USA for a more
detailed description of RACE methodology.

Substrate cDNA for the 5' RACE was synthesized from
mRNA primed with randomly generated hexamers including all
possible combinations of nucleotides at 7 positions. These

25   cDNA products were tailed at their 5' ends with dATP in a
terminal deoxytransferase reaction (GIBCO BRL, Grand Island,
New York, USA). Two rounds of PCR amplification were
performed on the tailed cDNA in which the 3' antisense primer
consisted of a bipartite oligonucleotide (poly d(T)17 plus

30   Hind III recognition site) designed to anneal to the 5'
terminal poly d(A)s. The outer 5' antisense primer for the
first round of PCR consisted of a septadecamer corresponding
to a region 111-127 nucleotides downstream of the decapeptide
region. The oligonucleotide sequence for the outer primer was

35   CAGGGCACACTGTCCTC (Seq. ID No. 24). For the second round of
amplification, the inner 5' antisense primer was bipartite,
composed of a known sequence of ten nucleotides including a
restriction endonuclease cleavage site plus another 17

51

nucleotides 72-88 nucleotides downstream of the decapeptide
region of the preprohormone candidate. The oligonucleotide
sequence for the inner primer was GCACGAATTCCGAAGCTATGAGCAGTC
(Seq. ID No. 25). PCR products were prepared for sequencing
5   (as above) and screened for the presence of the innermost
primer followed by antisense sequences from the candidate
clone and by antisense codons for the GnRH decapeptide. A
majority of the generated clones were positive for the
[His^5,Trp^7,Tyr^8]-GnRH encoding region and extended
10   approximately 135 more nucleotides before ending in the poly
d(T)/Hind III primer-sequence. Only one clone was isolated
containing preprohormone sequence 3' to that region amplified
by 5' RACE.

15   <u>Example 6:   Sequence Analysis of the treeshrew cDNA encoding
the [His^5,Trp^7,Tyr^8]-GnRH preprohormone</u>
           Only one clone was isolated in Example 5 which
contained preprohormone sequence 3' to that region amplified
by 5' RACE. To confirm the sequence, we designed a
20   nondegenerate bipartite oligonucleotide whose 5' end consisted
of ten nucleotides including a restriction endonuclease
cleavage site and whose 3' end encoded residues 3-8 of the
decapeptide region. The sequence of the oligonucleotide was
GCACGAATTCGGTCCCACGGCTGGTAC (Seq. ID No. 26). Poly d(T)
25   primed cDNA was used as substrate in PCR amplification between
the above oligonucleotide and a bipartite poly d(T)/Hind III
primer downstream. Products were prepared, sequenced and
screened as before resulting in many positive clones
containing the same sequence as that found in the primary
30   downstream clone and ending in polyadenylated tails.
           The fullest sequence of this preprohormone was
obtained by aligning overlapping regions from at least ten
consensus 5' RACE templates with at least ten consensus
sequences generated in the first and second 3' PCR
35   amplifications. Sequences were aligned (Color Alignment
Macros, M. Haygood) and differences attributed to PCR-error
were assessed. The deduced amino acid sequence is shown in
Seq. ID No. 18. As with GnRH preprohormones previously

isolated, a signal sequence precedes the decapeptide, followed
by a conserved proteolytic processing site and an associated
peptide. (See *Comparative Biology and Evolutionary
Relationships of Treeshrews*, W.P. Luckett, ed., Plenum Press,
5   New York (1980).) Treeshrews are part of the super order
Archonta, which includes primates, flying lemurs, bats and
elephant shrews. Treeshrews are thus very closely related to
primates, yet primitive. As a consequence, they are very
frequently used to discover information about molecules,
10   processes, etc., which may link much more primitive rodents
with primates. Thus, [Ser^8]-GnRH preprohormone may be present
in primates including humans.

Example 7: Isolation of a cDNA encoding *H. burtoni* [Ser^8]-GnRH
15   preprohormone
            To obtain nucleotide sequences encoding a [Ser^8]-
GnRH-like peptide from *H. burtoni*, a novel polymerase chain
reaction (PCR) strategy using brain regions known to contain
GnRH neuronal populations was employed (see Fig. 4 for a
20   schematic view of *H. burtoni* brain). Animals were sacrificed
and whole brains removed as described in White, S.A. &
Fernald, R.D. *J. Neurosci.* (1993) 13:434-441. *H. burtoni* mRNA
was isolated from the preoptic area, brain tissue known to
contain the GnRH neuronal population which projects to the
25   pituitary. cDNA synthesis was primed with a bipartite
oligonucleotide whose 3' domain consisted of a homopolymer of
d(T)9 residues, while the 5' domain comprised a known sequence
of 14 nucleotides which included a restriction endonuclease
recognition site. The resulting cDNA was used as substrate
30   for nested PCR. In both rounds of amplification, the
downstream primer was as described above. In the first PCR
reaction, the 5' end of the primer contained a known
restriction enzyme recognition sequence and the 3' sequence
was a mixture of 48 tetradecamers representing all possible
35   coding sequences for the first five amino acids of [Ser^8]GnRH.
(See Powell, J.F.F., *et al.* Regulatory Peptides, submitted.)
The sequence of the this pool of oligonucleotides was as
follows: GCACGAATTCCA A/G CA T/C TGGTCNTA T/C GG (Seq. ID No.

27). The product of this reaction served as substrate for
nested reactions where the new upstream primer was bipartite.
The 5' end of this primer also contained a known restriction
enzyme recognition sequence while the 3' end comprised a pool

5   of 384 tetradecamers representing all possible coding
combinations for residues 5-8 of the decapeptide. The
sequences of these oligonucleotides are represented in the
following two sequences: GCACGAATTCTA T/C GGN C/T TNTCNCC
(Seq. ID No. 28) and GCACGAATTCTA T/C GGN C/T TNAG C/T CC

10   (Seq. ID No. 29).

        PCR products were separated by electrophoresis in a
2% GTG agarose gel (FMC Bioproducts, Rockville, Maine, USA)
and products >250 bases were electroeluted and subcloned into
M13 phage vector for sequence analysis (see Bond et al. (1991)

15   *J. Mol. Endocrinol.*, 5:931-937). Nucleotide sequences were
analyzed for the presence of the second upstream primer
followed by the codons for the final amino acid of the
decapeptide, glycine, and the following three amino acid
residues gly, lys, arg (see figure 2). These residues follow

20   the decapeptide sequence in the other cloned GnRH
preprohormones and serve as substrates for posttranslational
processing. Several independent clones from 3 separate
first-round and 7 second-round PCR reactions contained these
landmarks followed by an open reading frame of 201 nucleotides

25   (67 amino acids). To confirm the identity of these clones as
the [Ser[8]]-GnRH preprohormone, templates were visually
compared after alignment in a spreadsheet (Color Alignment
Macros, M. Haygood, Scripps Institute of Oceanography, San
Diego, California, USA) and a region of consensus was chosen

30   from which to generate new primers for 5' rapid amplification
of cDNA ends (RACE). See Frohman et al. in (1993) *Methods in
Enzymology* Volume 218, Wu, R., editor, Academic Press, Inc.,
San Diego, California, USA for a more detailed description of
RACE methodology.

35   The bipartite primer used to make the substrate cDNA
for the 5' RACE reactions consisted of a randomly generated
hexamer including all possible combinations of nucleotides at
7 positions. These cDNA products were tailed at their 5' ends

with dATP in a terminal deoxytransferase reaction (GIBCO BRL, Grand Island, New York, USA). Two rounds of PCR amplification were performed on the tailed cDNA in which the 3' antisense primer consisted of a bipartite oligonucleotide (poly d(T)17

5   plus Bam HI recognition site), designed to anneal to the 5' terminal poly d(A)s. The outer 5' antisense primer for the first round of PCR consisted of 18 nucleotides corresponding to a region of high consensus amongst the candidate preprohormone templates. The sequence of this primer is

10   CATATTGCCCAGTGTGTC (Seq. ID No. 30). For the second round of amplification, the inner 5' antisense primer was bipartite, composed of a known sequence of 14 nucleotides including a restriction endonuclease cleavage site plus another 18 nucleotides from the preprohormone candidate which were 3' to

15   but did not overlap with the first selected sequence. The nucleotide sequence of this primer is GCACGAATTCGTGTCTGAGAAGTTGTCC (Seq. ID No. 31). PCR products were prepared for sequencing as described above, and were screened for the presence of the innermost primer followed by

20   antisense sequences from the candidate templates and by antisense codons for the GnRH decapeptide itself.

Example 8:   Sequence Analysis of the cDNA encoding *H. burtoni* [Ser[8]]-GnRH preprohormone

25   Approximately 80% of the generated clones were positive for the [Ser[8]]-GnRH-encoding region and extended approximately 140 more nucleotides before ending in the poly d(T)/BamHI primer sequence. The fullest sequence of this preprohormone was obtained by aligning overlapping regions

30   from consensus 5' RACE templates with consensus sequences generated in the primary PCR amplification. Sequences were aligned (Color Alignment Macros) and differences attributed to PCR-error were assessed. The sequence of the full length cDNA is shown as Seq. ID No. 19 and the deduced amino acid sequence

35   is shown as Seq. ID. No. 20. In each case, a signal sequence precedes one of the decapeptide forms, followed by a conserved proteolytic processing site and an associated peptide.

Example 9:   Localization of [Ser[8]]-GnRH preprohormone mRNA
expression in *H. Burtoni* brain sections by *in situ*
hybridization

     The identity of the [Ser[8]]-GnRH preprohormone
5   obtained above as that encoding the GnRH contained within
preoptic area GnRH-ir neurons which govern gonadotropin
secretion from the pituitary was confirmed through *in situ*
analysis on *H. burtoni* brain sections. These neurons are
known to enlarge or shrink in size depending on the social and
10 reproductive state of the fish (see Davis & Fernald (1991) *J.
Neurobiol.* 21:1180-1188). Tissue sections were prepared from
both a dominant and a subordinate animal, which contain either
large or small GnRH immunoreactive (GnRH-ir) neurons,
respectively. Social status was determined by behavioral
15 observations. Animals were sacrificed, brains removed and
tissue fixed as previously described in Example 4, herein.
Cryostat sections (40µm) were mounted on poly(L-lysine)-coated
slides for hybridization.

     A hybridization probe was generated by PCR
20 amplification of a consensus 5' RACE product cloned into M13
using lac and rev lac primers. Following gel electrophoresis
performed as described in Example 7, herein, a single band of
the correct size (ca. 210 bases) was electroeluted and
fragments were subcloned into pSK+ (Stratagene, San Diego,
25 California, USA). Double-stranded sequencing confirmed that
several clones contained the 5' RACE insert and one was chosen
as a template for generation of an antisense digoxygenin-UTP
(Boehringer Mannheim, Indianapolis, Indiana, USA) riboprobe.
The riboprobe was prepared as follows: The plasmid was
30 linearized with BamHI (GIBCO/BRL, Grand Island, New York, USA)
and purified using the Wizard clean-up system from Promega,
Madison, Wisconsin, USA). 300 ng was used for transcription
of an RNA probe with T7 polymerase (GIBCO/BRL, Grand Island,
New York, USA) and a 1xNTP labelling mixture
35 (Boehringer-Mannheim, Indianapolis, Indiana, USA) as described
in Example 4, herein.

     Hybridizations were carried out at high stringency
(60°C in 60% formamide) under conditions slightly modified

from those suggested by the digoxygenin manufacturer (Boehringer Mannheim, Indianapolis, Indiana, USA). 150 μl of hybridization solution was applied to slides containing five to six brain sections. After hybridization, 2 washes were

5   done in 2x SSC, followed by washes in 1.5x and 1x SSC respectively at 60°C with a final wash at room temperature in 1x SSC. All washes were for 20 minutes. Slides were dehydrated, coverslipped and viewed using a light microscope.

Figure 5 shows a panel of midsagittal sections from

10   $H.$ $burtoni$ brain, focusing on the three regions which contain GnRH-ir cell populations (see Davis & Fernald (1990), supra). The top three regions were hybridized to the [Ser[8]]-GnRH riboprobe as described above. Within this top tier, the first section is split, showing preoptic area cells labeled with the

15   [Ser[8]]-GnRH riboprobe from both a dominant and a subordinate male fish. They reveal that the [Ser[8]]-GnRH transcript is expressed in the preoptic region within a cell population that exhibits neuronal size plasticity correlated with social state. The bottom two panels show hybridization of the

20   riboprobe in the terminal nerve area and the mesencephalon regions of the $H.$ $burtoni$ brain of dominant males. Thus, in $H.$ $burtoni$, the three different genes encoding GnRH are expressed in three distinct regions of the brain.

While not wishing to be bound by theory, the in $situ$

25   hybridization data supports an important reproductive role for the hypothalamic-preoptic form of GnRH, [Ser[8]]-GnRH, in the cichlid fish $H.$ $burtoni$. In this species, preoptic GnRH-ir cells grow and shrink with social and reproductive state. Dominant males have large GnRH-producing cells, large testes,

30   and are reproductively active. Subordinate males have small GnRH-producing cells, small testes and do not mate. Preoptic GnRH gene expression may therefore not only reflect the reproductive state of the animal, but may also be responsive to social cues.

35   Also while not wishing to be bound by theory, the distribution of [His[5],Trp[7],Tyr[8]]-GnRH mRNA in $H.$ $Burtoni$ brain, coupled with other information, suggests that this form of GnRH may coordinate reproductive behavior with reproductive

state. [His^5,Trp^7,Tyr^8]-GnRH is the most widespread and
ancient GnRH isoform, having been immunologically detected in
caudal brain regions of all non-mammalian vertebrates studied
to date, often localized to a midbrain neuronal population.

5   While in goldfish these cells project to the median eminence
and result in the delivery of [His^5,Trp^7,Tyr^8]GnRH (in
addition to the hypothalamic form) to the pituitary, this
isoform is not present in the pituitary of *H. burtoni*.
Neither is it widely detected in the pituitaries of other

10   species. This fact stands in contrast to the marked efficacy
of the [His^5,Trp^7,Tyr^8]GnRH isoform in causing release of
gonadotropins in cultures of dispersed pituitary cells. Thus,
while this isoform is capable of acting at pituitary GnRH
receptors, it seldom has the *in vivo* opportunity to

15   demonstrate its functional potency. However, because of this
biological activity, nucleic acids encoding the
[His^5,Trp^7,Tyr^8]GnRH precursor, as well as the nucleic acids
encoding the [Ser^8]-GnRH precursor, may be useful in the
production of transgenic animals, including transgenic fish.

20

Example 9: Northern blot analysis of *H. burtoni* brain tissue
for the [Ser^8]-GnRH Precursor

        To determine the size of the [Ser^8]-GnRH mRNA
precursor relative to the sizes of the other GnRH

25   preprohormones in *H. burtoni*, Northern analyses were performed
at high stringency as described in Example 3, herein.
Poly(A)+ RNA was isolated from ventral and dorsal brain
regions using the FastTrak kit from Invitrogen Corporation,
San Diego, California. 1.5 µg aliquots were loaded onto

30   replicate lanes of a denaturing 2.5% agarose gel for size
separation. The gel was prepared as a Northern blot using
capillary transfer. Individual lanes were subjected to
high-stringency hybridizations (50% formamide, 62°C) with
riboprobes for each of the 3 GnRH preprohormones in *H.*

35   *burtoni*, either alone and in combination. Riboprobes were
synthesized with T7 polymerase (GIBCO BRL, Grand Island, New
York, USA), incorporating [a-32P]UTP (Amersham Corporation,
Arlington Heights, Illinois, USA) to a specific activity of 3

X 108 dpm/µg. Hybridization mixtures contained 107 dpm per
ml. The [Ser^8]-GnRH riboprobe labeled a band of approximately
550 bases while the size of the [Trp^7,Leu^8]GnRH and
[His5,Trp7,Tyr8]GnRH transcripts are approximately 500 and 590

5   bases, respectively.

         The above examples are provided to illustrate the
invention but not to limit its scope. Other variants of the
invention will be readily apparent to one of ordinary skill in

10   the art and are encompassed by the appended claims. All
publications, patents, and patent applications cited herein
are hereby incorporated by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT:
        (A) NAME: The Board of Trustees of Leland Stanford, Jr.
            University,
            And
            State of Oregon, acting by and through The
            Oregon State Board of Higher Education on behalf
            of The Oregon Health Sciences University

        (B) STREET: 900 Welch Road, Suite 350
        (C) CITY: Palo Alto
        (D) STATE: California
        (E) COUNTRY: U.S.A.
        (F) POSTAL CODE (ZIP): 94304-1858
        (G) TELEPHONE: (415) 723-0651
        (H) TELEFAX: (415) 725-7295
        (I) TELEX:

    (ii) TITLE OF INVENTION: Nucleic acids Encoding
        [His-5,Try-7,Tyr-8]-GnRH Preprohormone and
        [Ser-8]-GnRH preprohormone and
        Their Uses

    (iii) NUMBER OF SEQUENCES: 31

    (iv) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

    (v) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER: WO not yet designated
        (B) FILING DATE:
        (C) CLASSIFICATION:

    (vi) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER: US 08/147,771
        (B) FILING DATE: 05-NOV-1993

    (vii) ATTORNEY/AGENT INFORMATION:
        (A) NAME: Weber, Kenneth A.
        (B) REGISTRATION NUMBER: 31,677
        (C) REFERENCE/DOCKET NUMBER: 14210-000400PC

    (viii) TELECOMMUNICATION INFORMATION:
        (A) TELEPHONE: (415) 543-9600
        (B) TELEFAX: (415) 543-5043

(2) INFORMATION FOR SEQ ID NO:1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 563 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (genomic)

    (iii) HYPOTHETICAL: NO

    (vi) ORIGINAL SOURCE:

      (A) ORGANISM: Haplochromis burtoni

   (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 135..389

   (ix) FEATURE:
        (A) NAME/KEY: misc_feature
        (B) LOCATION: 243..389
        (D) OTHER INFORMATION: /note= "Nucleotide sequence that
             encodes the GAP peptide."

   (ix) FEATURE:
        (A) NAME/KEY: misc_feature
        (B) LOCATION: 1..563
        (D) OTHER INFORMATION: /note= "cDNA sequence that contains
             nucleotide sequence that encodes
             GnRH{5-His,7-Trp,8-Tyr} from Haplochromis

   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GACTGTCAGC GCAACTGGAT TTTAGCACTA AATCCACCAA AGGAAAAGAA CATTTTGAAG         60

TGAACCCCTG CAGGTACACT GAGGGAAACT TGGACTGATA AAGCTGTGAA ATCTAAGACT        120

AAGGTGGGAA TATC ATG TGT GTG TCT CGA CTG GCT TTG CTC TTG GGG CTG        170
              Met Cys Val Ser Arg Leu Ala Leu Leu Leu Gly Leu
               1           5                   10

CTT CTC TGT GTG GGG GCT CAG CTG TCC TTT GCC CAG CAC TGG TCC CAT        218
Leu Leu Cys Val Gly Ala Gln Leu Ser Phe Ala Gln His Trp Ser His
          15                  20                  25

GGT TGG TAT CCT GGA GGA AAA AGG GAG CTG GAC TCC TTT GGC ACA TCA        266
Gly Trp Tyr Pro Gly Gly Lys Arg Glu Leu Asp Ser Phe Gly Thr Ser
     30                  35                  40

GAG ATT TCA GAG GAG ATT AAG CTG TGT GAA GCA GGG GAA TGC AGC TAC        314
Glu Ile Ser Glu Glu Ile Lys Leu Cys Glu Ala Gly Glu Cys Ser Tyr
45                  50                  55                  60

CTG AGA CCC CAG AGG AGG AGT ATC CTG AGA AAC ATT CTT CTG GAT GCC        362
Leu Arg Pro Gln Arg Arg Ser Ile Leu Arg Asn Ile Leu Leu Asp Ala
              65                  70                  75

TTA GCC AGA GAG CTT CAG AAG AGA AAG TGACATCTTT CCAGAGCCTC              409
Leu Ala Arg Glu Leu Gln Lys Arg Lys
              80                  85

TTTTCTATAG TAACCCACTT CCCTTTGTAT TTCTGCCTTG ACGTGATTTT GTGATCATCT        469

GGCCTTGCTG TTTGTAATGT TTGTCAGTAA ATTTGTCCTG TTTTTTTCGA TGTGAAAATT        529

GTGTCCCAAA ATAAATATCT ATTTTTATAT TAAA                                  563
```


(2) INFORMATION FOR SEQ ID NO:2:

      (i) SEQUENCE CHARACTERISTICS:
         (A) LENGTH: 85 amino acids
         (B) TYPE: amino acid
         (D) TOPOLOGY: linear

     (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO. 2:

```
Met Cys Val Ser Arg Leu Ala Leu Leu Leu Gly Leu Leu Leu Cys Val
 1               5                   10                  15

Gly Ala Gln Leu Ser Phe Ala Gln His Trp Ser His Gly Trp Tyr Pro
            20                  25              30

Gly Gly Lys Arg Glu Leu Asp Ser Phe Gly Thr Ser Glu Ile Ser Glu
        35                  40              45

Glu Ile Lys Leu Cys Glu Ala Gly Glu Cys Ser Tyr Leu Arg Pro Gln
    50              55              60

Arg Arg Ser Ile Leu Arg Asn Ile Leu Leu Asp Ala Leu Ala Arg Glu
65                  70              75                  80

Leu Gln Lys Arg Lys
                85
```

(2) INFORMATION FOR SEQ ID NO:3:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 90 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: peptide

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Haplochromis burtoni

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..90
        (D) OTHER INFORMATION: /note= "Name:
            PreproGnRH{7-Trp,8-Leu}."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Met Glu Ala Gly Ser Arg Val Ile Met Gln Val Leu Leu Leu Ala Leu
 1               5                   10                  15

Val Val Gln Val Thr Leu Ser Gln His Trp Ser Tyr Gly Trp Leu Pro
            20                  25              30

Gly Gly Lys Arg Ser Val Gly Glu Leu Glu Ala Thr Ile Arg Met Met
        35                  40              45

Gly Thr Gly Gly Val Val Ser Leu Pro Asp Glu Ala Asn Ala Gln Ile
    50              55              60

Gln Glu Arg Leu Arg Pro Tyr Asn Ile Ile Asn Asp Asp Ser Ser His
65                  70              75                  80

Phe Asp Arg Lys Lys Arg Phe Pro Asn Asn
                85                  9?
```

(2) INFORMATION FOR SEQ ID NO:4:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Mammal

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:5:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Chicken (I)

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH{8-Gln}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Glu His Trp Ser Tyr Gly Leu Gln Pro Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:6:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Salmon

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH{7-Trp,8-Leu}"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Glu His Trp Ser Tyr Gly Trp Leu Pro Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:7:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Catfish

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH{5-His,8-Asn}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Glu His Trp Ser His Gly Leu Asn Pro Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:8:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Chicken (II)

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH{5-His,7-Trp,8-Tyr}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Glu His Trp Ser His Gly Trp Tyr Pro Gly
1   5   10

(2) INFORMATION FOR SEQ ID NO:9:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Dogfish

    (ix) FEATURE:
        (A) NAME/KEY: Peptide

        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note= "GnRH{5-His,7-Trp,8-Leu}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

    Glu His Trp Ser His Gly Trp Leu Pro Gly
    1   5   10

(2) INFORMATION FOR SEQ ID NO:10:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Lamprey

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note=
            "GnRH{3-Tyr,5-Leu,6-Glu,7-Trp,8-Lys}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

    Glu His Tyr Ser Leu Glu Trp Lys Pro Gly
    1   5   10

(2) INFORMATION FOR SEQ ID NO:11:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 10 amino acids
        (B) TYPE: amino acid
        (D) TOPOLOGY: unknown

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: N-terminal

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Lamprey

    (ix) FEATURE:
        (A) NAME/KEY: Peptide
        (B) LOCATION: 1..10
        (D) OTHER INFORMATION: /note=
            "GnRH{3-Tyr,5-His,6-Asp,7-Trp,8-Lys}"

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

    Glu His Tyr Ser His Asp Trp Lys Pro Gly
    1   5   10

(2) INFORMATION FOR SEQ ID NO:12:

```
        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 8 amino acids
            (B) TYPE: amino acid
            (D) TOPOLOGY: unknown

       (ii) MOLECULE TYPE: protein

        (v) FRAGMENT TYPE: N-terminal

       (vi) ORIGINAL SOURCE:
            (A) ORGANISM: Alpha-yeast mating factor


       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

        His Trp Leu Glu Leu Lys Pro Gly
        1                   5

(2) INFORMATION FOR SEQ ID NO:13:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 14 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (genomic)



       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CARCAYTGGT CNCA                                                    14

(2) INFORMATION FOR SEQ ID NO:14:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 14 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (genomic)



       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CAYGGNTGGT AYCC                                                    14

(2) INFORMATION FOR SEQ ID NO:15:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 15 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (genomic)



       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCAGAAGCTT CAGCT                                                   15
```

(2) INFORMATION FOR SEQ ID NO:16:

  (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 29 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

  (ii) MOLECULE TYPE: DNA (genomic)

  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGGAATGCAG CTACCTGAGA CCCCAGAGG   29

(2) INFORMATION FOR SEQ ID NO:17:

  (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 422 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

  (ii) MOLECULE TYPE: cDNA

  (ix) FEATURE:
    (A) NAME/KEY: CDS
    (B) LOCATION: 72..338
    (D) OTHER INFORMATION: /product= "The
      [His-5,Trp-7,Tyr-8]-GnRH preprohormone from
      Treeshrew"

  (ix) FEATURE:
    (A) NAME/KEY: misc_feature
    (B) LOCATION: 60..62
    (D) OTHER INFORMATION: /note= "Encodes potential second
      initiator methionine."

  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

CTCGAGCCAG AAGGAGCCAC CCTACCTATA GCCTCTTCCA CTGCTGTCCC CGTCCTGCCA 60

TGGCCAGTTC C ATG CTG GGC TTC CTC CTC CTG CTG CTG CTG CTG ATG GCT 110
      Met Leu Gly Phe Leu Leu Leu Leu Leu Leu Leu Met Ala
      1   5   10

GCC CAC CCT GGA CCC TCG GAG GCC CAG CAT TGG TCC CAC GGC TGG TAC 158
Ala His Pro Gly Pro Ser Glu Ala Gln His Trp Ser His Gly Trp Tyr
  15   20   25

CCT GGA GGA AAG CGA GCC TCC AAC TCA CCC CAG GAC CCT CAA AGT GCC 206
Pro Gly Gly Lys Arg Ala Ser Asn Ser Pro Gln Asp Pro Gln Ser Ala
30   35   40   45

CTT AGG CCC CCA GCC CCC AGC GCA GCC AGA CTG CTC ATA GCT TCC GAA 254
Leu Arg Pro Pro Ala Pro Ser Ala Ala Arg Leu Leu Ile Ala Ser Glu
      50   55   60

GCG CTG CTC TGG CTT CCC CCG AGG ACA GTG TGC CCT GGG AGG GCA GGA 302
Ala Leu Leu Trp Leu Pro Pro Arg Thr Val Cys Pro Gly Arg Ala Gly
      65   70   75

```
CCA CAG CAG GAT GGT CTC TCC GCA GGA AGC AGC ACC TGATGCGGAC           348
Pro Gln Gln Asp Gly Leu Ser Ala Gly Ser S.   Thr
        80                      85
```

```
ACTGCTGAGC GCAGCCGGAG CGCCGCGCCC CGCCGCCGTC CCAATAAAGC CGTGAGATTC     408
```

```
CCGAAAAAAA AAAA                                                      422
```


(2) INFORMATION FOR SEQ ID NO:18:

      (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 89 amino acids
          (B) TYPE: amino acid
          (D) TOPOLOGY: linear

     (ii) MOLECULE TYPE: protein

     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
Met Leu Gly Phe Leu Leu Leu Leu Leu Leu Met Ala Ala His Pro
 1               5                 10                  15

Gly Pro Ser Glu Ala Gln His Trp Ser His Gly Trp Tyr Pro Gly Gly
        20              25                  30

Lys Arg Ala Ser Asn Ser Pro Gln Asp Pro Gln Ser Ala Leu Arg Pro
        35              40                  45

Pro Ala Pro Ser Ala Ala Arg Leu Leu Ile Ala Ser Glu Ala Leu Leu
    50              55                  60

Trp Leu Pro Pro Arg Thr Val Cys Pro Gly Arg Ala Gly Pro Gln Gln
65              70                  75                  80

Asp Gly Leu Ser Ala Gly Ser Ser Thr
                85
```

(2) INFORMATION FOR SEQ ID NO:19:

      (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 491 base pairs
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: single
          (D) TOPOLOGY: linear

     (ii) MOLECULE TYPE: cDNA

     (ix) FEATURE:
          (A) NAME/KEY: CDS
          (B) LOCATION: 71..364
          (D) OTHER INFORMATION: /product= "The [Ser-8]-GnRH
              preprohormone from H. burtoni"

     (ix) FEATURE:
          (A) NAME/KEY: misc_feature
          (B) LOCATION: 47..49
          (D) OTHER INFORMATION: /note= "Encodes potential second
              initiator methionine."

     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
TTAGACTTCA CAAAGGACAG CAGAAGAGAT CAGAAGTTCT TGTCTAATGC ACAGAAGCTT     60
```

68

```
TATCCTCAGA ATG GCT GCA AAA ATC TTG GCA CTG TGG CTG CTG CTC GCA        109
           Met Ala Ala Lys Ile Leu Ala Leu Trp Leu Leu Leu Ala
           1               5                   10

GGG ACG GTG TTT CCA CAG GGC TGC TGT CAG CAC TGG TCA TAC GGA CTG       157
Gly Thr Val Phe Pro Gln Gly Cys Cys Gln His Trp Ser Tyr Gly Leu
     15                  20                  25

AGC CCA GGA GGG AAG AGG GAT CTG GAC AAC TTC TCA GAC ACA CTG GGC       205
Ser Pro Gly Gly Lys Arg Asp Leu Asp Asn Phe Ser Asp Thr Leu Gly
30                  35                  40                  45

AAT ATG GTT GAA GAG TTC CCA CGC GTC GAA GCA CCT TGC AGT GTT TTC       253
Asn Met Val Glu Glu Phe Pro Arg Val Glu Ala Pro Cys Ser Val Phe
                50                  55                  60

GGT TGT GCA GAG GAA TCA CCT TTT GCC AAA ATG TAC AGA GTG AAA GGA       301
Gly Cys Ala Glu Glu Ser Pro Phe Ala Lys Met Tyr Arg Val Lys Gly
            65                  70                  75

CTT CTT GCG AGT GTG GCC GAA AGG AAA ATG GAC ACC GGA CAT TCA AGA       349
Leu Leu Ala Ser Val Ala Glu Arg Lys Met Asp Thr Gly His Ser Arg
        80                  85                  90

AAT GAA AGA TTT CTT TGATTCTACA TTTCATTTTT TATATGAGCA TAAAACATTT       404.
Asn Glu Arg Phe Leu
        95

TTTTGTGAAT GTTGCTCTTG TCTTATTATC TAAAATATAA ATAAAAGCTT TCAACTCACT     464

GAAAAAAAAA AAAAAAAAAA AAAAACC                                         491
```

(2) INFORMATION FOR SEQ ID NO:20:

      (i) SEQUENCE CHARACTERISTICS:
          (A) LENGTH: 98 amino acids
          (B) TYPE: amino acid
          (D) TOPOLOGY: linear

     (ii) MOLECULE TYPE: protein

     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```
Met Ala Ala Lys Ile Leu Ala Leu Trp Leu Leu Leu Ala Gly Thr Val
1               5                   10                  15

Phe Pro Gln Gly Cys Cys Gln His Trp Ser Tyr Gly Leu Ser Pro Gly
            20                  25                  30

Gly Lys Arg Asp Leu Asp Asn Phe Ser Asp Thr Leu Gly Asn Met Val
        35                  40                  45

Glu Glu Phe Pro Arg Val Glu Ala Pro Cys Ser Val Phe Gly Cys Ala
    50                  55                  60

Glu Glu Ser Pro Phe Ala Lys Met Tyr Arg Val Lys Gly Leu Leu Ala
65                  70                  75                  80

Ser Val Ala Glu Arg Lys Met Asp Thr Gly His Ser Arg Asn Glu Arg
                85                  90                  95

Phe Leu
```

(2) INFORMATION FOR SEQ ID NO:21:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 24 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: DNA (primer)

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GCACGAATTC CARCAYTGGT CNCA   24

(2) INFORMATION FOR SEQ ID NO:22:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 24 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: DNA (primer)

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCACGAATTC CARCAYTGGA GYCA   24

(2) INFORMATION FOR SEQ ID NO:23:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 24 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: DNA (primer)

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCACGAATTC CAYGGNTGGT AYCC   24

(2) INFORMATION FOR SEQ ID NO:24:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 17 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

        (ii) MOLECULE TYPE: DNA (primer)

        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CAGGGCACAC TGTCCTC   17

(2) INFORMATION FOR SEQ ID NO:25:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 27 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (primer)

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCACGAATTC CGAAGCTATG AGCAGTC   27

(2) INFORMATION FOR SEQ ID NO:26:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 27 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (primer)

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCACGAATTC GGTCCCACGG CTGGTAC   27

(2) INFORMATION FOR SEQ ID NO:27:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 27 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (primer)

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GCACGAATTC CARCAYTGGT CNTAYGG   27

(2) INFORMATION FOR SEQ ID NO:28:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 24 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (primer)

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GCACGAATTC TAYGGNYTNT CNCC   24

(2) INFORMATION FOR SEQ ID NO:29:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 24 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (primer)

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GCACGAATTC TAYGGNYTNA GYCC   24

(2) INFORMATION FOR SEQ ID NO:30:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 18 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (primer)

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CATATTGCCC AGTGTGTC   18

(2) INFORMATION FOR SEQ ID NO:31:

        (i) SEQUENCE CHARACTERISTICS:
            (A) LENGTH: 28 base pairs
            (B) TYPE: nucleic acid
            (C) STRANDEDNESS: single
            (D) TOPOLOGY: linear

       (ii) MOLECULE TYPE: DNA (primer)

       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GCACGAATTC GTGTCTGAGA AGTTGTCC   28

WHAT IS CLAIMED IS:

1   1.   An isolated nucleic acid encoding a vertebrate
2   [His^5,Trp^7,Tyr^8]-GnRH preprohormone.

1   2.   A composition according to claim 1 wherein said
2   nucleic acid encodes a full-length [His^5,Trp^7,Tyr^8]-GnRH
3   preprohormone.

1   3.   A composition according to claim 1 wherein said
2   preprohormone consists of the amino acid sequence depicted in
3   Seq. ID No. 2.

1   4.   A composition according to claim 1 wherein said
2   preprohormone is of fish origin.

1   5.   An isolated nucleic acid encoding a vertebrate
2   [His^5,Trp^7,Tyr^8]-GnRH preprohormone GAP peptide.

1   6.   A composition according to claim 5 wherein said
2   nucleic acid encodes a full-length [His^5,Trp^7,Tyr^8]-GnRH
3   preprohormone GAP peptide.

1   7.   A composition according to claim 6 wherein said
2   nucleic acid encodes the GAP peptide as shown in Figure 2.

1   8.   An isolated vertebrate [His^5,Trp^7,Tyr^8]-GnRH
2   preprohormone.

1   9.   A composition according to claim 8 wherein said
2   preprohormone is specifically immunoreactive with antibodies
3   raised against an immunogen consisting essentially of a
4   polypeptide of Seq ID No. 2.

1   10.   A composition according to claim 8 wherein said
2   preprohormone is recombinantly produced.

73

1   11. A composition according to claim 8 wherein said
2   preprohormone is of fish origin.

1   12. A composition according to claim 8 wherein said
2   preprohormone is full-length.

1   13. An isolated vertebrate [His^5,Trp^7,Tyr^8]-GnRH
2   preprohormone GAP peptide.

1   14. A composition according to claim 13 wherein
2   said GAP peptide is competent to bind antibodies raised
3   against an immunogen consisting essentially of a GAP peptide
4   as shown in Figure 2.

1   15. A composition according to claim 13 wherein
2   said GAP peptide is recombinantly produced.

1   16. A composition according to claim 13 wherein
2   said GAP peptide is of fish origin.

1   17. A composition according to claim 13 wherein
2   said GAP peptide is full-length.

1   18. An antibody specifically immunoreactive with a
2   vertebrate [His^5,Trp^7,Tyr^8]-GnRH preprohormone.

1   19. A composition according to claim 18 wherein
2   said antibody is specifically immunoreactive with a vertebrate
3   [His^5,Trp^7,Tyr^8]-GnRH preprohormone GAP peptide.

1   20. A nucleic acid probe capable of selectively
2   hybridizing to a nucleic acid encoding a vertebrate GnRH
3   preprohormone.

1   21. The composition of claim 20 wherein said
2   nucleic acid consists of Seq. ID No. 1.

1   22.   The composition of claim 20 wherein said
2   nucleic acid consists of a GAP peptide cDNA sequence as shown
3   in Seq. ID No. 1.

1   23.   A transgenic non-human animal having increased
2   reproductive capacity due to the expression of a DNA construct
3   encoding a vertebrate [His^5,Trp^7,Tyr^8]-GnRH preprohormone
4   introduced into said animal or an ancestor of said animal.

1   24.   The non-human animal of claim 23 wherein said
2   animal is a fish.

1   25.   A method of detecting a vertebrate
2   [His^5,Trp^7,Tyr^8]-GnRH preprohormone in a biological sample
3   comprising the steps of:
4   a)   contacting said biological sample with an
5   antibody specifically immunoreactive with a vertebrate
6   [His^5,Trp^7,Tyr^8]-GnRH preprohormone;
7   b)   incubating said antibody with said biological
8   sample to form an antibody:[His^5,Trp^7,Tyr^8]-GnRH preprohormone
9   complex; and
10   c)   detecting said complex.

1   26.   A method according to claim 25 wherein said
2   biological sample is of fish origin.

1   27.   A method of detecting a nucleic acid encoding
2   a vertebrate [His^5,Trp^7,Tyr^8]-GnRH preprohormone in a
3   biological sample comprising:
4   a)   contacting said biological sample with a nucleic
5   acid probe capable of selectively hybridizing to said nucleic
6   acid encoding a vertebrate [His^5,Trp^7,Tyr^8]-GnRH
7   preprohormone;
8   b)   incubating said nucleic acid probe with the
9   biological sample to form a hybrid of the nucleic acid probe
10 with complementary nucleic acid sequences present in the
11 biological sample; and

12   c) determining the extent of hybridization of the
13   nucleic acid probe to the complementary nucleic acid
14   sequences.

1   28. A method according to claim 27 wherein said
2   biological sample is of fish origin.

1   29. A composition according to claim 1 wherein said
2   preprohormone is of mammalian origin.

1   30. A composition according to claim 1 wherein said
2   preprohormone consists of the amino acid sequence depicted in
3   Seq. ID No. 18.

1   31. A composition according to claim 8 wherein said
2   preprohormone is of mammalian origin.

1   32. A composition according to claim 8 wherein said
2   preprohormone consists of the amino acid sequence depicted in
3   Seq. ID No. 18.

1   33. An isolated nucleic acid encoding a vertebrate
2   [Ser^8]-GnRH preprohormone.

1   34. A composition according to claim 33 wherein
2   said preprohormone is of fish origin.

1   35. A composition according to claim 33 wherein
2   said preprohormone consists of the amino acid sequence
3   depicted in Seq. ID No. 20.

1   36. An isolated vertebrate [Ser^8]-GnRH
2   preprohormone.

1   37. A composition according to claim 36 wherein
2   said preprohormone is of fish origin.

1   38.   A composition according to claim 36 wherein
2   said preprohormone consists of the amino acid sequence
3   depicted in Seq. ID No. 20.

Fig. 1:

1a

GnRH form	Source	1	2	3	4	5	6	7	8	9	10	Sequence ID No.
GnRH	Mammal	pE	H	W	S	Y	G	L	R	P	GNH2	4
GnRH [⁸Gln]	Chicken (I)	pE	H	W	S	Y	G	L	Q	P	GNH2	5
GnRH [⁷Trp⁸Leu]	Salmon	pE	H	W	S	Y	G	W	L	P	GNH2	6
GnRH [⁸His⁹Asn]	Catfish	pE	H	W	S	H	G	L	N	P	GNH2	7
GnRH [⁸His⁷Trp⁸Tyr]	Chicken (II)	pE	H	W	S	H	G	W	Y	P	GNH2	8
GnRH [⁸His⁷Trp⁸Leu]	Dogfish	pE	H	W	S	H	E	W	L	P	GNH2	9
GnRH [⁸Tyr⁵Leu⁶Glu⁷Trp⁸Lys]	Lamprey	pE	H	Y	S	L	D	W	K	P	GNH2	10
GnRH [⁹Tyr⁵His⁶Asp⁷Trp⁸Lys]	Lamprey	pE	H	Y	S	H	G	W	K	P	GNH2	11
α-yeast mating factor		H	H	W		L	E	L	K	P	G	12

(Amino acid sequence, positions 1–10)

1b PCR 5' Chains

GnRH form	1	2	3	4	5	6	7	8	9	10	Sequence ID No.
GnRH [⁷Trp⁸Leu]	pE	H	W	S	Y	G	W	L	P	GNH2	13
GnRH [⁸His⁷Trp⁸Tyr]	pE	H	W	S	H	G	W	Y	P	GNH2	14

round 1: 5'-CAAG CAT/C TGG TCX AGT/C CA-3' GGX TGG CAT/C

round 2: 5'-CAT/C GGX TGG TAT/C CC-3'

Fig. 2:

<div align="center">

-20   -10   +1   10

</div>

GnRH(^{7}Trp^{8}Leu):   MEAGSRVIMQVLLLALVVQVTLS **QHWSYGWLPG GKR**

GnRH(^{5}His^{7}Trp^{8}Tyr):   MCVSRLALLLGLLLCVGAQLSFA **QHWSHGWYPG GKR**

<div align="center">

20   30   40   50   60

</div>

SVGELEATIRMMGTGGVVSLPDEANAQIQERLRPYNIINDDSSHFDRKKRFPNN*

ELDSFGTSEISEEIKLCEAGECSYLRPQRRSILRNILLDALARELQKRK*

- 0.53 kb

1 2 3 4 5 6 7

FIG. 3.

Fig. 4:

[His⁵, Trp⁷, Tyr⁸]-GnRH   [Trp⁷, Leu⁸]-GnRH

Fig. 5:

**PREOPTIC AREA
NON-TERRITORIAL MALE**

**PREOPTIC AREA
TERRITORIAL MALE**

**TERMINAL NERVE
TERRITORIAL MALE**

**MESENCEPHALON
TERRITORIAL MALE**

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :Please See Extra Sheet.
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S. : 800/2, DIG1; 536/23.51, 24.31; 530/313, 324, 387.1, 388.1; 435/69.1, 172.3; 436/513

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C.	DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Molecular Endocrinology, Volume 5, issued 1991, C. Bond et al., "Characterization of Complementary DNA Encoding the Precursor for Gonadotropin-Releasing Hormone and its Associated Peptide from a Teleost Fish", pages 931-937, see entire document.	1-38
A	Society for Neuroscience Abstracts, Volume 19, part 2, issued 1993, S. White et al., "A Second Gene for GNRH: Complementary DNA and Expression Pattern for the Pre-Prohormone in a Teleost Fish", page 1623, see entire abstract.	1-38

[X] Further documents are listed in the continuation of Box C.   [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
04 JANUARY 1995	17 FEB 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer CHARLES C. P. RORIES, Ph.D.
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Journal of Molecular Endocrinology, Volume 11, issued 1993, I. Dunn et al., "Characterization of the Chicken Preprogonadotrophin-Releasing Hormone-I Gene", pages 19-29, see entire document.	1-38
Y	Endocrine Reviews, Volume 14, No. 2, issued 1993, N. Sherwood et al., "Origin of Mammalian Gonadotropin-Releasing Hormones", pages 241-254, see entire document.	1-38
Y	Regulatory Peptides, Volume 42, issued 1992, S. Ngamvongchon et al., "Structure-Function Studies of Five Natural, Including Catfish and Dogfish, Gonadotropin-Releasing Hormones and Eight Analogs on Reproduction in Thai Catfish (*Clarias macrocephalus*)", pages 63-73, see entire document.	1-38
Y	Proceedings of the National Academy of Sciences USA, Volume 89, issued July 1992, D. Lovejoy et al., "Distinct Sequence of Gonadotropin-Releasing Hormone (GnRH) in Dogfish Brain Provides Insight into GnRH Evolution", pages 6373-6377, see entire document.	8-19, 25, 26, 31, 32, 36-38
Y	Science, Volume 252, issued 21 June 1991, T. Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy", pages 1657-1662, see entire document.	9, 14, 18, 19, 25, 26
Y	BioTechniques, Volume 5, No. 3, issued 1987, B. Dunbar, "The Use of Two-Dimensional Electrophoresis Combined with Immunological Techniques", pages 218-226, see entire document.	9, 14, 18, 19, 25, 26
Y	BIO/TECHNOLOGY, Volume 10, issued February 1992, Shao J. Du et al., "Growth Enhancement in Transgenic Atlantic Salmon by the Use of an 'All Fish' Chimeric Growth Hormone Gene Construct", pages 176-181, see entire document.	10, 15, 23, 24

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A01K 67/00; A61K 38/09; C12N 15/00, 15/16; C07H 21/04; C07K 7/06, 14/575, 16/18, 16/26; C12P 21/06, 21/08;
G01N 33/53

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

800/2; 536/23.51, 24.31; 530/313, 324, 387.1, 388.1; 435/69.1, 172.3; 436/513

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, BIOSIS
  search terms: gnrh, gonadotropin(w)releasing(w)hormone, preprohormone, cdna, gene, fish, cichlid, ser, serine
DNA and Protein Sequence Data Banks searched for SEQ ID NO:s 1, 2, and 17-20.